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Summary 24 
Background 25 
Multiple new treatments have been recently investigated for Clostridium difficile infection 26 
(CDI). We aimed to compare and rank treatments for non-recurrent CDI in adults.  27 
Methods 28 
We performed a random effects network meta-analysis within a frequentist setting to obtain 29 
direct and indirect comparisons from trials. We searched MEDLINE, EMBASE, Web of 30 
Science, CENTRAL and clinicaltrials.gov for published and unpublished trials up to 30th 31 
June, 2017. We included randomised controlled trials of treatments for non-multiply 32 
recurrent CDI in adults, using the Cochrane risk of bias tool to appraise trial methodology. 33 
The primary outcome was sustained symptomatic cure, defined as the number of patients 34 
with resolution of diarrhoea minus the number with recurrence or death.  35 
Findings 36 
24 trials, involving 5361 patients and 13 different treatments were included in the final 37 
analysis. The overall quality of evidence was rated as moderate-low. For sustained 38 
symptomatic cure fidaxomicin (odds ratio [OR] 0·67, 95% confidence interval [CI] 0·55 to 39 
0·82) and teicoplanin (0·37, 0·14 to 0·94) were significantly better than vancomycin. 40 
Teicoplanin, ridinilazole, fidaxomicin, surotomycin and vancomycin were better than 41 
metronidazole (0·27, 0·10 to 0·70; 0·41, 0·19 to 0·88; 0·49, 0·35 to 0·68; 0·66, 0·45 to 0·97; 42 
0·73, 0·56 to 0·95). Bacitracin was inferior to teicoplanin and fidaxomicin, tolevamer was 43 
inferior to all agents apart from LFF571 and bacitracin. Global heterogeneity of the entire 44 
network was low, Cochrane Q = 15·70, p = 0·47. 45 
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Interpretation 46 
Fidaxomicin demonstrates the best chance of sustained symptomatic cure in non-multiply 47 
recurrent CDI with the strongest evidence base. It is better than vancomycin for all patients 48 
except those with severe CDI and could be considered as first line therapy. Metronidazole 49 
should not be recommended for treatment of CDI.   50 
Funding  51 
None 52 
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Introduction 65 
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Reclassification of Clostridium difficile as Clostridioides difficile has been recently 66 
proposed,1 but a preference for the established name prevails. Clostridium difficile infection 67 
(CDI) is increasing and is the most common healthcare associated infection in USA, and is 68 
rising in the developing world.2,3 In the USA there were 29, 000 deaths in 2011,4 and in 2014 69 
it posed a financial burden of 5·4 billion US dollars.5,6 For more than three decades 70 
metronidazole and vancomycin have been the principal treatment options for CDI. However, 71 
sub-optimal rates of sustained cure and the increasing prevalence and associated morbidity 72 
and mortality from CDI warranted the development and evaluation of new therapeutic agents.  73 
After demonstrating a higher sustained clinical cure rate than vancomycin, 74 
fidaxomicin was approved for CDI treatment in 2011.7 However, the long-term response was 75 
not achieved in a significant proportion of patients and research to develop multiple agents to 76 
achieve a lasting cure are ongoing. There have been many treatments evaluated in clinical 77 
trials for treating CDI, such as tolevamer, an orally taken toxin-binding polymer, as well as 78 
multiple directly acting antimicrobials: bacitracin, fusidic acid, surotomycin, ridinidazole, 79 
teicoplanin, LFF571, nitazoxanide, cadazolid and rifaximin.  80 
 Several pairwise comparison meta-analyses have investigated the efficacy of 81 
CDI treatments.8-12 However, they mostly focused on a subset of treatments investigated for 82 
this indication. In addition, there have been several novel and non-published trials which, to 83 
our knowledge, to date have not been included or synthesized in a systematic review. 84 
Furthermore, most of the agents do not have direct trial comparisons, making it impossible to 85 
generate a hierarchy of treatments through pairwise meta-analyses. We therefore performed a 86 
network meta-analysis (NMA) aiming to compare and rank treatments for non-multiply 87 
recurrent CDI in adults. 88 
 89 
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Methods 90 
Search strategy 91 
We searched MEDLINE, Embase, Web of Science, Cochrane Central Register of 92 
Controlled Trials (CENTRAL) and clinicaltrials.gov since database inception up to 30th June 93 
2017 for full papers, conference abstracts and proceedings describing therapeutic randomised 94 
controlled trials (RCTs) against CDI (Appendix, page 5). We searched the reference lists of 95 
systematic reviews of Clostridium difficile treatments published between 1st Jan 2012 and 96 
30th June 2017. To maximise the yield, both MeSH and free text terms were used and no 97 
language restrictions were applied. Non-English articles were translated. We searched 98 
pharmaceutical company databases, contacted pharmaceutical companies and study authors 99 
directly, where trials were registered, but not published. 100 
Two authors (TB, NB) independently reviewed and assessed the eligibility of titles, 101 
abstracts and studies deemed relevant for full text review. Any disagreements were resolved 102 
through discussion with the third author (VS). A systematic review and NMA was performed 103 
according to the guidelines and recommendations from the preferred reporting items for 104 
systematic reviews and network meta̺analyses (PRISMA) checklist.13 For the study 105 
protocol, see appendix, page 2.  106 
Inclusion and exclusion criteria 107 
Two authors (TB, NB) reviewed in full all RCTs investigating the therapeutic effects 108 
of at least two different treatments for CDI. Studies investigating pharmacological agents, 109 
probiotics, immunotherapy and faecal microbiota transfer (FMT) treatments were included if 110 
they met the following criteria. 111 
Inclusion criteria: 112 
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x Randomised controlled trial.  113 
x Adult patients (>18 years old). 114 
x Both primary symptomatic cure and recurrence of diarrhoea reported. 115 
x Confirmed CDI, defined as active diarrhoea AND positive Clostridium difficile 116 
nucleic acid amplification test OR positive Clostridium difficile cytotoxin assay result 117 
OR stool culture growing Clostridium difficile OR pseudomembranes seen on 118 
colonoscopy. 119 
x Only multiply recurrent or multiply relapsing Clostridium difficile patients were 120 
included. This patient group comprises a minority of patients with CDI and has very 121 
different prognosis from the overall patient cohort with CDI.  122 
Exclusion criteria: 123 
x Data not available for intention to treat analysis. 124 
x Prophylactic rather than therapeutic effect of the agent investigated. 125 
x Multiple active agents against CDI used simultaneously. 126 
Outcome measures 127 
Our primary outcome was sustained symptomatic cure, which was calculated as 128 
number of patients achieving a primary cure (resolution of diarrhoea per individual trial 129 
criteria) at the end of treatment minus the number of patients with recurrence (recurrence of 130 
diarrhoea or requirement for additional treatment) or death during the follow-up period. 131 
Secondary outcomes were primary cure and recurrence rate.  132 
Data extraction and methodological quality assessment 133 
Two authors (TB and NB) independently reviewed papers included in the final 134 
analyses and extracted relevant data (for list of data extracted see appendix, page 3).  135 
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The Cochrane risk of bias tool14 was used to assess the risk of bias (Appendix, page 136 
14) and Revman v5·015 to generate the risk of bias tables. We performed intention-to-treat 137 
analyses where drop-outs were assumed to be treatment failures. Any discrepancies with data 138 
extraction or risk of bias assessment were resolved through consensus decision with a third 139 
author (VS). 140 
Statistical analysis 141 
Multiple pairwise meta-analyses for antibiotics against Clostridium difficile have been 142 
recently reported by Nelson et al.8 and were not repeated here. Network meta-analyses allow 143 
the comparison of evidence from clinical studies where direct, head-to-head, data is not 144 
available, and enables the ranking of treatments in order of efficacy.16 We performed a 145 
random-effects NMA using a frequentist setting.17 :HXVHGWKHµ1HWPHWD¶SDFNDJHIRU5IRU146 
numerical data analysis.18 A random-effects model was used to obtain the relative treatment 147 
effects. Given its widespread use, vancomycin was chosen as a reference treatment. Forest 148 
plots were generated to illustrate the treatment effects compared to vancomycin. League 149 
tables were used to display the relative efficacy of all available pairwise comparisons of 150 
available treatments.18  151 
The P-score was used to rank treatments, which can have a value between 0 and 1, 152 
with a higher P-scores indicating a greater chance of being the best treatment.19 A scatter plot 153 
was used to spatially visualise the partial order of treatments with regards to primary cure and 154 
recurrence rates. NetmetaXL 1·6 ·120 was used to generate network graphs, which will be 155 
used to illustrate the evidence base. Treatment estimates are presented as odds ratios (ORs) 156 
with 95% confidence intervals.  157 
Sensitivity and subgroup analyses 158 
8 
 
We performed three pre-specified sensitivity analyses. Firstly, non-blinded studies 159 
were excluded, as resolution of diarrhoea is semi-objective outcome that can be adversely 160 
affected by absence of blinding. In another sensitivity analysis we excluded trials published 161 
before 2000. CDI incidence has markedly increased since 2000, coinciding with the 162 
emergence of the hypervirulent BI/NAP1/027 strain.21 We also excluded studies with <50 163 
participants in each study arm to test for small-study effects. In one post-hoc sensitivity 164 
analysis, we excluded RCTs performed before 1990.  165 
We further performed subgroup analyses and individual NMAs for patients with 166 
severe CDI, non-severe CDI, first CDI, non-first CDI, patients aged <65 years and >65 years. 167 
We used stratified patients into different severity categories as defined by each trial. These 168 
assessment criteria are summarized in the appendix, page 14. For subgroup analyses of 169 
fidaxomicin trials, we used review data12, as primary publications did not provide the 170 
recurrence rate. Insufficient data were available to perform inpatient/outpatient subgroup 171 
analyses.  172 
Assessment of heterogeneity and inconsistency  173 
$JHQHUDOLVHG&RFKUDQ¶V4VWDWLVWLFZas used to assess the homogeneity of 174 
multivariate meta-analysis.22 To identify single design and between design contributions to 175 
JOREDOKHWHURJHQHLW\LQWKHUDQGRPHIIHFWVPRGHOWKHJOREDO&RKUDQ¶V4VFRUHZDVIXUWKHU176 
decomposed into within design heterogeneity22 and between designs heterogeneity scores.23 177 
The between designs Q score was calculated based on a full design-by-treatment interaction 178 
random effects model,23 defined via a generalised methods of moments estimate of the 179 
between-studies variance tau^2.24 A network heat plot was used to visualise and identify the 180 
nodes of single-design inconsistency.22 We checked the consistency between direct and 181 
LQGLUHFWHYLGHQFHXVLQJµQRGH-VSOLWWLQJ¶25 A p-value of < 0.10 was considered as significant 182 
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in inconsistency assessment. Comparison-adjusted funnel plots were generated using STATA 183 
(version 14·0) to assess publication and small study bias. 184 
Role of the funding source 185 
The sponsor of the study had no role in study design, data collection, data analysis, data 186 
interpretation, or writing of the report. The corresponding author had full access to all the 187 
data in the study and had final responsibility for the decision to submit for publication. 188 
 189 
Results 190 
Our search identified 29, 976 references, of which, 19 publications, representing 20 191 
RCTs, were deemed eligible and were included in the final NMA (Figure 1; Appendix, page 192 
12). Two additional unpublished RCTs26, 27 were retrieved from the pharmaceutical company 193 
database, one of which was published 9 months after the search26. Further two unpublished 194 
RCTs were provided by pharmaceutical company and authors through direct communication. 195 
One trial was in Japanese, the rest were in English. In total 24 RCTs, with 5, 361 unique 196 
patients were included in the NMA. Included studies were published between 1983 and 2017 197 
and investigated 13 pharmacological interventions against CDI (Table 1). Follow up-time 198 
was between 21 and 30 days for all studies except Louie et al43 who reported outcomes at 56 199 
days and Guery et al26  at 90 days. Guery et al26 also reported results at 30 follow-up, which 200 
were used in our analysis to make them more comparable to other studies. None of the FMT, 201 
probiotic or immunotherapy trials met the inclusion criteria. All included trials had an active 202 
control.  203 
The network was reasonably balanced and interconnected: 5 treatments had more than 204 
400 patients, there were 11 loops. The mean study sample was 223 participants (range 12 ± 205 
629) (table 1). Vancomycin was the most frequent intervention, investigated in 21 RCTs 206 
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(N=2107), followed by metronidazole (7 RCTs, N=563) and fidaxomicin (6 RCTs, N=881). 207 
The mean participant age was 63 years and 53% were female (table 1). The duration of 208 
treatment ranged between 4 and 25 days, while the median duration of follow-up was 28 days 209 
(range 21-90). 71% trials were sponsored by industry, 8% jointly by government and industry, 210 
for 21% of trials funding information was not provided. Most RCTs were carried out in USA, 211 
Canada, Australia or Europe. NCT02179658 2016 RCT was carried in Japan, while Boix et 212 
al.,40 also recruited patients from 2 centres in the Middle East. 42% of trials were 213 
multinational.  214 
The overall quality of studies was moderate-low (figure 3; appendix, page 14, for 215 
supporting judgements). Random sequence generation procedures were adequate and clearly 216 
described in only 42% of RCTs, and 7/24 RCTs were non-blinded. 217 
The network for efficacy assessment of sustained symptomatic cure can be seen in 218 
figure 2. Network graphs for primary cure and recurrence were identical. All agents had at 219 
least one direct comparison with vancomycin. The summary of the pairwise comparisons is 220 
shown in the league table (table 2). Teicoplanin (OR 0·37, 95% CI 0·14 to 0·94) and 221 
fidaxomicin (OR 0·67, 95% CI 0·55 to 0·82) were significantly better than vancomycin in 222 
attaining a sustained symptomatic cure. Vancomycin was superior to metronidazole (OR 0·73, 223 
95% CI 0·56 to 0·95). Teicoplanin, ridinidazole, fidaxomicin and surotomycin were also 224 
more efficacious than metronidazole (table 2). Tolevamer was significantly inferior to all 225 
agents, apart from LFF571 and bacitracin. In our GRADE assessment, only fidaxomicin had 226 
high confidence in its treatment effect (appendix, page 41). Confidence in teicoplanin and 227 
ridinidazole treatment effects were rated as very low and moderate, respectively. 228 
Vancomycin ranked 7th and metronidazole 11th among 13 assessed agents.  229 
Secondary outcomes: Primary cure and recurrence 230 
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No treatment was significantly superior to vancomycin in achieving a primary 231 
symptomatic cure (Appendix, page 22). Tolevamer was inferior to all treatments and 232 
metronidazole was inferior to vancomycin.  233 
Fidaxomicin had significantly fewer recurrences than vancomycin and metronidazole 234 
(Appendix, page 24). Amongst 13 treatments, vancomycin and metronidazole ranked 9th and 235 
11th, respectively.  236 
Consistency of the NMA 237 
Heterogeneity for the entire NMA for sustained symptomatic cure, was not significant 238 
(Cochrane Q = 15·70, p = 0·47; tau^2 = 0). Between designs heterogeneity for sustained 239 
symptomatic cure was low (Cochrane Q 3·19, p = 0·87) and non-significant for all 11 loops 240 
(Appendix, page 21). Within designs heterogeneity (Cochrane Q = 12·61, p = 0·18) was 241 
higher due to significant pairwise vancomycin - metronidazole comparison heterogeneity 242 
(Cochrane Q = 3·94, p = 0·047). This heterogeneity originated from a markedly higher 243 
sustained symptomatic cure rate in metronidazole arm demonstrated in the non-blinded 244 
Teasley 1983 trial 41 than in other trials investigating metronidazole and vancomycin. In this 245 
trial 1:1 randomisation resulted in markedly lower number of participants in the 246 
metronidazole arm (45 vs 56). 247 
A heatplot identified only few faint nodes of direct - indirect evidence inconsistency 248 
(Appendix, page 20). This highlighted metronidazole - fusidic acid and fusidic acid - 249 
teicoplanin interactions that are influenced by results derived from a four-arm, non-blinded 250 
Wenisch et al. RCT.29 Wenisch et al. results demonstrated a high sustained cure for 251 
teicoplanin and significantly higher recurrence rate for patients treated with fusidic acid than 252 
subsequent moderate-high quality Wullt et al. 2004 RCT30 comparing fusidic acid and 253 
metronidazole.  254 
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Direct versus indirect comparisons of treatment estimates did not reveal any 255 
significant differences (Appendix, page 27). A comparison-adjusted funnel plot did not 256 
demonstrate any small trial or publication bias (Appendix, page 30). For primary cure global 257 
heterogeneity was low (Cochrane Q = 13·52, p = 0·63; tau^2 = 0) (Appendix, page 23). For 258 
recurrence, global heterogeneity was significant (Cochrane Q = 24·02, p = 0·09; tau^2 = 259 
0·089), mainly due to significant between design heterogeneity, which was present in 9 out of 260 
11 loops (Appendix, page 25). In isolation, recurrence NMA results should be interpreted 261 
with caution. 262 
Sensitivity analysis 263 
Exclusion of non-blinded trials eliminated all teicoplanin and LFF571 RCTs from the 264 
NMA (Appendix, page 31). With similar P-scores, ridinilazole and fidaxomicin remained the 265 
top ranking treatments. Estimates of other effect sizes did not change significantly and global 266 
heterogeneity was low (Cochrane Q = 7·97, p = 0·44, tau^2 = 0). Ridinilazole and 267 
fidaxomicin ranked the highest again, when small studies (<50 patients in each arm) and 268 
RCTs published before 2000 were excluded. Due to low total participant numbers in 269 
ridinilazole treatment arm (N=64), confidence intervals of its treatment effect estimates were 270 
very wide. All sensitivity analyses resulted only in minimal changes in treatment effect 271 
estimates from the ones seen in the overall NMA (Appendix, pages 31-34).  272 
Subgroup analyses 273 
A limited number of trials had available data for subgroup evaluation and there was 274 
no subgroup data for bacitracin, teicoplanin, rifaximin, LFF571 and cadazolid. In subgroup 275 
analyses fidaxomicin was superior to vancomycin in non-severe CDI, primary and non-276 
primary CDI and in patients aged both <65 and >65 (Table 3). Ridinilazole was significantly 277 
better that vancomycin in attaining a sustained symptomatic cure in non-severe CDI and <65 278 
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age group. Ridinilazole ranked as the best treatment for severe, non-severe CDI, first CDI 279 
and patients <65 year old. Fidaxomicin ranked as the best treatment in non-first CDI and 280 
patients aged >65. Metronidazole was inferior to fidaxomicin in all subgroups. For full 281 
subgroup analyses and rankograms see appendix, pages 35-40.  282 
 283 
Discussion 284 
This study provides the most up-to-date and comprehensive synthesis of evidence for 285 
pharmacological treatment of Clostridium difficile infection. In addition to published trials, 286 
our NMA also included results from 3 unpublished trials that were not included in previous 287 
pairwise meta-analyses. In the final selection stage we excluded three recent high quality 288 
RCTs49, 50 investigating the influence of monoclonal antibodies against Clostridium difficile 289 
toxins along with antibiotic therapy for achieving a primary cure and preventing the 290 
recurrence of CDI. In these trials participants were randomized only into monoclonal 291 
antibody or placebo arm, but vancomycin, metronidazole or fidaxomicin therapy was 292 
administered according to clinical assessment rather than being assigned randomly. These 293 
groups are therefore not comparable to the studies included in our network. 294 
  Based on P-score, in our NMA, teicoplanin ranked as the best treatment, 295 
ridinilazole and fidaxomicin, ranked second and third, respectively. However, the treatment 296 
effect estimates for teicoplanin (GRADE: very low; Appendix, page 41) were only based on 297 
two small RCTs, comprising 55 individuals, with high risk of bias, and were performed in 298 
1992 and 1996. The 95% CI of the effect of teicoplanin is wide, reflecting the relatively small 299 
number of subjects contributing to the network analysis so the results should be interpreted 300 
with caution.  The original RCTs29, 45 used intravenous teicoplanin solution orally. Since 2013, 301 
oral teicoplanin liquid form has been licensed to be used for CDI in Europe, however, not in 302 
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USA.51 Oral teicoplanin and vancomycin have been investigated in an earlier cohort study by 303 
de Lalla in 1989.52  Both antibiotics showed excellent clinical response rates (100%), but the 304 
relapse rate was 13% vs 0% in vancomycin vs teicoplanin recipients, respectively.  305 
Ridinilazole (GRADE: moderate), a CDI specific antibiotic, has only been studied in two 306 
RCTs and 64 patients.32, 48 A phase 3 trial is expected to commence in 2018. Ridinilazole did 307 
not demonstrate a high primary cure rate, but had the lowest chance of recurrence among all 308 
agents. Having been investigated in 6 RCTs11, 26, 27, 33, 46, 48 and nearly 900 patients, 309 
fidaxomicin (GRADE: high) has the strongest evidence base to support its use. It is 310 
significantly better than vancomycin, metronidazole, bacitracin and tolevamer in achieving a 311 
sustained cure. On the basis of our results, tolevamer and bacitracin cannot be recommended 312 
for treatment of CDI.  313 
Surotomycin and LFF571, two newly developed agents, did not demonstrate any 314 
superiority over vancomycin. At the time of writing, only phase 2 trial36 results for cadazolid 315 
were fully available.  However, a press release53 indicates that cadazolid did not meet its 316 
primary endpoint in comparison with vancomycin in one of two large international phase 3 317 
trials with more than 1200 patients combined (NCT01987895, NCT01983683).  318 
Since 2014, the European Society of Clinical Microbiology and Infectious Diseases 319 
(ESCMID) guidelines have recommended metronidazole as the first line treatment for initial 320 
non-severe CDI.54 In recent guidelines,55 vancomycin or fidaxomicin have been 321 
recommended as first line treatment for CDI; metronidazole is only recommended for an 322 
initial episode of non-severe CDI in settings where access to vancomycin or fidaxomicin is 323 
limited.56  In our NMA, metronidazole ranked only 11th among 13 treatments in achieving a 324 
sustained symptomatic cure, was significantly inferior to five other agents and was inferior to 325 
fidaxomicin in all subgroup analyses performed. Previous reports suggested high faecal 326 
metronidazole concentrations with intravenous administration and proposed its usage when 327 
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oral administration is not possible.57, 58 Results of this NMA do not support use of 328 
metronidazole as first-line CDI therapy in oral form and intravenous form is equally unlikely 329 
to be effective. For non-initial CDI, ESCMID guidelines recommend vancomycin or 330 
fidaxomicin.54 In our NMA, fidaxomicin had a significantly higher sustained cure rate than 331 
vancomycin in this patient group and might be considered as a better first-line agent. 332 
Furthermore, a very recent Guery et al. RCT26 compared an extended duration dosage of 333 
fidaxomicin with conventional vancomycin, and demonstrated a high sustained symptomatic 334 
cure rate, owing to very low, and significantly reduced CDI recurrence rate compared with 335 
vancomycin (7/131 vs 30/136). The recurrence in a subgroup of patients with NAP1/BI/027 336 
strain was not different between fidaxomicin and vancomycin arms in phase 3 trial.33 337 
However, this trial was not powered to determine the effectiveness of fidaxomicin against 338 
certain C difficile strains. The use of fidaxomicin as a first line CDI agent is partially 339 
supported by the overall body of economic evaluations, in which it was more cost-effective 340 
than either vancomycin or metronidazole.59 341 
The overall consistency of NMA for sustained symptomatic cure was good with none 342 
of the loops showing significant heterogeneity. Nevertheless, there are several limitations to 343 
this study. We included all randomised controlled trials, even those without sufficient 344 
blinding. Teicoplanin, which ranked as the best treatment in overall NMA, was lost from 345 
NMA in sensitivity analysis, when non-blinded trials were excluded. Secondly, the majority 346 
of trials were sponsored by industry. Exclusion of these trials would have left almost no trials 347 
to compare and this sensitivity analysis could not be performed. Thirdly, no unified CDI 348 
severity assessment systems was used among RCTs. This makes non-severe versus severe 349 
CDI subgroup assessment less reliable. Finally, in our NMA we included all treatments that 350 
were investigated as monotherapy against CDI, even though some of them are no longer in 351 
clinical development for CDI treatment or their use is limited by licensing barriers: 352 
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teicoplanin is not licensed for CDI treatment in USA, Merck has discontinued the 353 
development of surotomycin after its international phase 3 trial, while ridinilazole is still to 354 
undergo a phase 3 trial. However, inclusion of data from these trials allows us to obtain more 355 
accurate treatment effect estimates for the remaining members of the NMA. Given its 356 
promise in small low quality RCTs, oral teicoplanin should be investigated in a large well 357 
designed RCT to establish its sustained symptomatic cure effect more accurately.   358 
The findings of this NMA suggest that of the currently approved treatments, 359 
fidaxomicin has the strongest evidence for being the most effective treatment in providing a 360 
long-term cure against CDI. Apart from financial affordability, there is little ground for using 361 
metronidazole as first-line treatment against CDI. Early data for ridinilazole suggest this can 362 
potentially become a new efficacious treatment against CDI, but results of its phase 3 trials 363 
are still awaited. 364 
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Tables and figures 579 
Figure 1. Study selection  580 
  581 
Table 1. Summary of the included trials.  582 
 583 
BAC ± bacitracin, BD ± twice a day, CAD - cadazolid, FID- fidaxomicin, FUA ± fusidic acid, IND ± industry, GOV ± government, MET ± 584 
metronidazole, NIT ± nitazoxanide, OC ± oral capsule, OL- oral liquid, QDS ± four time a day, RFX ± rifaximin, RID ± ridinidazole, SUR ±585 
 surotomycin, TDS ± three times a day, TEIC ± teicoplanin, TOL ± tolevamer, VAN ± vancomycin 586 
*Although authors present follow-up results up to 90 days, we use 30 day follow-up results for our analysis to maximize the transitivity bet587 
ween network meta-analysis studies 588 
 589 
Figure 2. Network of eligible comparisons for efficacy of treatments of C. Diff.  590 
 591 
 592 
Line width is proportional to the number of trials comparing every pair of treatments. The size of the circle is pr593 
oportional to the number of patients assigned. BAC ± bacitracin, CAD- cadazolid, FID- fidaxomicin, FUA ± fusi594 
dic acid, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, SUR ± surotomycin, TEIC ± teicoplani595 
n, TOL ± tolevamer, VAN ± vancomycin. 596 
 597 
 598 
 599 
Figure 3. Summary of risk of bias assessment.  600 
 601 
 602 
Johnson et al. 2014 reported two trials ± 301 and 302. Both were of identical design. For supporting judgements 603 
see appendix, page 14. 604 
 605 
Table 2. League table of pairwise comparisons in network meta-analysis for attaining a 606 
sustained symptomatic cure. 607 
 608 
Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, 609 
which are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence 610 
26 
 
intervals. Significant pairwise comparisons are highlighted. BAC ± bacitracin, CAD - cadazolid, FID - 611 
fidaxomicin, FUE ± Fusidic acid, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, SUR ± 612 
surotomycin, TEIC ± teicoplanin, TOL ± tolevamer, VAN ± vancomycin. 613 
 614 
 615 
Table 3. Summary of subgroup analyses for sustained symptomatic cure compared to vancomyc616 
in.  617 
 618 
 619 
Effect sizes provided in odds ratios. Significant interactions are highlighed. FID ± Fidaxomicin, FUA ± Fusidic 620 
acid, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, SUR ± surotomycin, TOL ± tolevamer 621 
 622 
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Research in context 
Evidence before this study 
We performed a systematic literature search on Pubmed, EMBASE and Web of Science for 
systematic reviews and meta-analyses of treatments for Clostridioides difficile infection 
(CDI). We performed search for period between 1st Jan 2010 and 1st June 2017 using MeSH 
WHUPVÄ&ORVWULGLXPGLIILFLOH³DQGÄ0HWD-DQDO\VLV³DVZHOODVNH\ZRUGVÄ&',³Ä&'$'³DQG
ÄV\VWHPDWLFUHYLHZ³ÄPHWDDQDO\VLV³$OOILHOGVUHVWULFWLQJWKHVHDUFKWRPHWD-analyses and 
systematic reviews. Only meta-analyses of randomized controlled trials for CDI treatment 
were included. 418 records were identified, of which 4 met the inclusion criteria. 1 meta-
analysis focused on head-to-head comparison of fidaxomicin, metronidazole and 
vancomycin, 1 on fidaxomicin and vancomicin only and 2 meta-analyses on all antibiotics 
trialled for CDI. We found no network meta-analyses. 
The most comprehensive Cochrane meta-analysis by Nelson and colleagues published 
in 2017 performed pairwise comparisons for different antibiotics, only where direct evidence 
was available. There have been no analyses of indirect evidence for treatments of primary 
CDI, to rank the treatments in order of efficacy.  
Added value of this study  
This is the first network meta-analysis of pharmacological treatments for Clostridium 
difficile infection. It comprises of 13 different treatments and allows comparison and ranking 
of efficacy for treatments that did not have direct head-to-head comparison. We included four 
trials that have not been published and were not included in previous, pairwise meta-analyses. 
Our study emphasizes that fidaxomicin is the treatment with the strongest evidence for 
achieving a sustained symptomatic cure in CDI, while metronidazole is poorer than many 
other agents at achieving a sustained symptomatic cure. We also demonstrate that teicoplanin 
Research in context
Click here to download Necessary additional data: Research in context.docx
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and ridinidazole could potentially be effective treatments for CDI, however, their routine 
implementation should await results from larger trials.  
Implications of all the available evidence 
Our findings indicate that fidaxomicin and vancomycin can be recommended as a first 
line treatments for Clostridium difficile infection. Metronidazole cannot be recommended for 
treatment of CDI. In Europe, if fidaxomicin or vancomycin are unavailable, treatment with 
oral teicoplanin might be attempted.   
 
29976 references identified by 
database search 
23004 titles screened 
9972 duplicates excluded 
21445 titles excluded 
1559 abstracts reviewed 
144 full-text articles reviewed 
1415 abstracts excluded 
19 articles (describing 20 RCTs) and 
4 unpublished RCTs included in the 
network meta-analysis 
125 full-text articles excluded: 
44 duplicate reports of the same data 
24 included patients with only recurrent CDI 
22 cohort studies 
10 single arm studies 
5 preventive effect study 
5 case report or case series 
4 only different doses of the same drug compared 
3 dual active treatment 
3 reviews 
1 healthy subjects 
1 included patients with various causes of post Ȃ
operative diarrhoea 
1 placebo group taken from another trial 
1 total number of patients not available for ITT analysis 
1 study report not available 
2 unpublished RCTs from trial registries 
2 unpublished RCTs from data inquiries to 
authors and pharmaceutical companies 
Figure 1
VAN
RFX
SUR
BAC
FUA
FID
CAD
MET
LFF571
TOL
RIDTEIC
NIT
Figure 2
Figure 3
Study 
Treatment, dose, form, frequency, duration 
(days), sample size 
Follow-up 
(days ) Female 
Mean age 
(years) 
Severe 
CDI 
Location Sponsorship 
Zar 2007 
28
 
VAN 125mg OL QDS 10d, N=82 
MET 250mg OC QDS 10d, N=90 N/A 41% 58 48% USA N/A 
Wenisch 1996 
29
 
VAN 500mg OC TDS 10d, N=31 
MET 500mg OC TDS 10d, N=31 
TEIC 400mg OL BD 10d, N=28 
FUA 500mg OC TDS 10d, N=29 
30 48% 42 N/A Austria N/A 
Wullt 2004 
30
 
MET 400mg OC TDS 7d, N=64 
FUA  250mg OC TDS 7d, N=67 
30 65% 58 N/A Sweden GOV + IND 
Young 1985 
31
 
VAN 125mg OC QDS 7d, N=21 
BAC 20000 UNITS OC QDS 4d N=21 28 N/A 62 N/A Australia N/A 
Vickers 2017 
32
 
VAN 125mg OC QDS 10d, N=50 
RID 200mg OC BD 10d, N=50 30 66% 57 16% USA IND 
Louie 2011 
33
 
VAN 125mg OC QDS 10d, N=327 
FID 200mg OC BD 10d, N=302 
28 56% 62 39% USA, Canada IND 
Cornely 2012 
34
 
VAN 125mg OC QDS 10d, N=265 
FID 200mg OC BD 10d, N=270 
28 61% 63 24% USA, Canada, Europe IND 
Mullane 2015 
35
 
VAN 125mg OC QDS 10d, N=26 
LFF571 200mg OC QDS 10d, N=46 30 65% 58 20% USA, Canada IND 
Louie 2015 36 VAN 125mg OC QDS 10d, N=22 
CAD  250, 500, 1000mg OL BD 10d, N=62 
30 39% 51 9% Canada, Germany, 
United Kingdom, USA 
IND 
Musher 2006 
37
 
MET 250mg OC QDS 10d, N=44 
NIT 500mg OC BD 7d or 10d, N=98 21 24% 68 N/A USA IND 
Musher 2009 
38
 
VAN 125mg OC QDS 10d, N=27 
NIT 500mg OC BD 10d, N=23 21 34% 63 41% USA IND 
Dudley 1986 
39
 
VAN 500mg OL QDS 10d, N=31 
BAC 25000 UNITS OL QDS 10d, N=31 N/A 60% 69 N/A USA N/A 
Boix 2017 
40
 
VAN 125mg OC QDS 10d, N=298 
SUR 250mg OC BD 10d, N=308 30 40% 61 34% 
USA, Canada, Europe, 
Middle-East 
IND 
Teasley 1983 
41
 
VAN 500mg OC QDS 10d, N=56 
MET 250mg OC QDS 10d, N=45 21 N/A 65 N/A USA GOV + IND 
Lee 2016 
42
 
VAN 125mg OC QDS 10d, N=70 
SUR 125, 250mg OCs BD 10d, N=139 
28 63% N/A 6% USA, Canada IND 
Louie 2006 
43
 
VAN 125mg OC QDS 10d, N=96 
TOL 3g, 6g OCs TDS 14d, N=190 56 55% 67 1% USA, Canada, UK IND 
Johnson 2014 
(301) 
44
 
VAN 125mg OC QDS 10d, N=140 
MET 375mg OC QDS 10d, N=149 
TOL 3g OL TDS 14d, N=285 
28 53% 62 34% 
USA, Canada, Europe, 
Canada 
IND 
Johnson 2014 
(302) 
44
 
VAN 125mg OC QDS 10d, N=126 
MET 375mg OC QDS 10d, N=140 
TOL 3g OL TDS 14d, N=278 
28 54% 68 24% USA, Canada, Europe, 
Canada 
IND 
Table 1 - 24th Apr
De Lalla 1992 
45
 
VAN 500mg OL QDS 10d, N=24 
TEIC 100mg OL BD 10d, N=27 
30 69% N/A N/A Italy N/A 
Thabit 2016 
46
 
VAN 125mg OC QDS 10d, N=5 
FID 200mg OC BD 10d, N=7 28 50% 70 N/A USA IND 
NCT02179658 
2016 
(unpublished) 
27
 
VAN 125mg OL QDS 10d, N=109 
FID 200mg OC BD 10d, N=106 
28 52% 75 22% Japan IND 
Guery 2017  
26
 
VAN 125mg OC QDS 10d, N=181 
FID 200mg OC BD 5d, then OD every 2 days 
for 20d, N=183 
 
90* 58% 75 27% Europe, Turkey IND 
Pardi 2012 
(unpublished) 
47
 
VAN 125mg OC QDS 10d, N=119 
RFX 400mg OC TDS 10d, N=119 
28 61% 60 N/A USA IND 
Mitra 2017 
(unpublished) 
48
 
RID 200mg OC BD 10d, N=14 
FID 200mg OC BD 10d, N=13 
30 N/A N/A 7% UK IND 
 
 
 0·9386 
            
TEIC 0·8280 
           
0·65 [0·20; 2·12] RID 0·7922 
          
0·55 [0·21; 1·44] 0·84 [0·41; 1·74] FID 0·6951 
         
0·53 [0·13; 2·15] 0·82 [0·23; 2·86] 0·97 [0·34; 2·78] CAD 0·5820 
        
0·41 [0·15; 1·10] 0·63 [0·29; 1·35] 0·75 [0·53; 1·06] 0·77 [0·26; 2·24] SUR 0·5405 
       
0·39 [0·13; 1·21] 0·60 [0·23; 1·58] 0·72 [0·37; 1·41] 0·74 [0·22; 2·49] 0·96 [0·48; 1·94] NIT 0·4850 
      
0·37 [0·14; 0·94] 0·57 [0·28; 1·15] 0·67 [0·55; 0·82] 0·69 [0·25; 1·94] 0·90 [0·68; 1·19] 0·93 [0·49; 1·78] VAN 0·4296 
     
0·34 [0·11; 1·01] 0·52 [0·21; 1·28] 0·62 [0·34; 1·12] 0·64 [0·20; 2·06] 0·83 [0·44; 1·55] 0·86 [0·37; 2·02] 0·92 [0·53; 1·61] RFX 0·3794 
    
0·31 [0·11; 0·89] 0·48 [0·19; 1·23] 0·57 [0·30; 1·09] 0·59 [0·18; 1·95] 0·77 [0·39; 1·50] 0·80 [0·35; 1·84] 0·85 [0·47; 1·57] 0·93 [0·41; 2·11] FUA 0·3635 
   
0·29 [0·08; 1·15] 0·45 [0·13; 1·52] 0·54 [0·20; 1·46] 0·55 [0·13; 2·29] 0·72 [0·26; 1·99] 0·75 [0·23; 2·42] 0·80 [0·30; 2·13] 0·87 [0·28; 2·68] 0·94 [0·30; 2·97] LFF571 0·2411 
  
0·27 [0·10; 0·70] 0·41 [0·19; 0·88] 0·49 [0·35; 0·68] 0·51 [0·17; 1·46] 0·66 [0·45; 0·97] 0·68 [0·37; 1·27] 0·73 [0·56; 0·95] 0·79 [0·43; 1·47] 0·86 [0·48; 1·52] 0·92 [0·33; 2·53] MET 0·2006 
 
0·22 [0·06; 0·77] 0·34 [0·11; 1·00] 0·40 [0·17; 0·94] 0·42 [0·11; 1·55] 0·54 [0·23; 1·28] 0·56 [0·20; 1·59] 0·60 [0·26; 1·36] 0·65 [0·24; 1·76] 0·70 [0·25; 1·95] 0·75 [0·21; 2·70] 0·82 [0·35; 1·94] BAC 0·0245 
0·15 [0·06; 0·39] 0·23 [0·11; 0·48] 0·27 [0·20; 0·37] 0·28 [0·10; 0·80] 0·36 [0·25; 0·53] 0·38 [0·20; 0·73] 0·40 [0·32; 0·51] 0·44 [0·24; 0·80] 0·47 [0·25; 0·87] 0·50 [0·18; 1·39] 0·55 [0·42; 0·72] 0·67 [0·28; 1·58] TOL 
Table 2
 
 
RID FID NIT MET SUR TOL FUA 
Severe CDI 0·37 [0·05; 3·06] 0·57 [0·30; 1·11] 0·64 [0·09; 4·37] 1·47 [0·78; 2·78] 4·33 [0·14; 137·06] 2·67 [1·30; 5·49] N/A 
Non-Severe CDI 0·36 [0·14; 0·93] 0·47 [0·33; 0·66] 0·80 [0·15; 4·26] 1·57 [1·06; 2·32] 0·59 [0·31; 1·12] 2·86 [2·00; 4·08] N/A 
Initial CDI 0·43 [0·18; 1·05] 0·52 [0·38; 0·70] 0·71 [0·18; 2·76] 1·34 [0·90; 1·99] 0·56 [0·28; 1·11] 3·10 [2·18; 4·40] 0·84 [0·37; 1·90] 
Non-initial CDI 0·37 [0·04; 3·61] 0·45 [0·24; 0·84] 1·50 [0·06; 40·63] 1·80 [0·86; 3·75] 0·76 [0·18; 3·23] 1·74 [0·90; 3·37] N/A 
>65 year old 0·79 [0·22; 2·77] 0·54 [0·38; 0·77] N/A 1·61 [1·00; 2·58] 1·01 [0·39; 2·60] 2·90 [1·91; 4·41] N/A 
<65 year old 0·26 [0·08; 0·80] 0·47 [0·31; 0·71] N/A 1·30 [0·78; 2·18] 0·45 [0·20; 1·02] 2·52 [1·60; 3·96] N/A 
Table 3
1 
 
 
 
 
Comparative efficacy of treatments for Clostridium difficile infection: a network meta-analysis 
 
Tumas Beinortas, Nicholas Burr, Mark Wilcox, Venkatamaran Subramanian 
 
Supplementary appendix to the manuscript 
  
 Page 
Appendix 1. Study protocol 2 
Appendix 2. Search strategy 5 
Appendix 3. Search flow diagrams 9 
Appendix 4. Individual trial definitions of cure and CDI severity, participant ethnicity, prevalence 
of previous CDI and inpatients at onset 12 
Appendix 5. Support for judgements in risk of bias assessments 14 
Appendix 6. Cumulative risk of bias 19 
Appendix 7. Forest plot and heterogeneity assessment for sustained symptomatic cure 20 
Appendix 8. Forest plot, heterogeneity assessment and league table for primary cure 22 
Appendix 9. Forest plot, heterogeneity assessment and league table for recurrence 24 
Appendix 10. Scatter plot 26 
Appendix 11. Direct versus indirect evidence for sustained symptomatic cure 27 
Appendix 12. Sustained symptomatic cure NMA after removal of Teasley 1983 RCT 29 
Appendix 13. Comparison-adjusted funnel plot for sustained symptomatic cure 30 
Appendix 14. Sensitivity analysis for sustained symptomatic cure: non-blinded studies excluded 31 
Appendix 15. Sensitivity analysis for sustained symptomatic cure: trials published before 1990 
excluded 32 
Appendix 16. Sensitivity analysis for sustained symptomatic cure: trials published before 2000 
excluded 33 
Appendix 17. Sensitivity analysis for sustained symptomatic cure: trials with less than 50 patients 
in each arm were excluded 34 
Appendix 18. Subgroup analyses 35 
Appendix 19. Confidence in sustained symptomatic cure estimates by GRADE system 41 
Appendix 20. Results of individual studies 44 
Appendix 21. Ongoing RCTs 45 
Appendix
Click here to download Necessary additional data: Appendix.pdf
2 
 
Appendix 1. Study protocol 
 
Comparative efficacy of treatments for Clostridium difficile infection: a network meta-analysis 
Study protocol 
 
Background 
 
Clostridium difficile infection (CDI) has become the commonest iatrogenic infection in the developed world.1 Multiple treatments 
have been investigated and trialled in this patient group. Previous meta-analyses compared only interventions that had direct head-
to-head comparisons in randomised controlled trials. Such approach does not allow the comparison of efficacy of treatments that 
have not been compared directly in randomised controlled trials and therefore does not permit generation of treatment hierarchies. 
In addition, agents like tolevamer, a polymer, have been omitted from previous meta-analyses. To compare the efficacy of all 
pharmacological treatments against CDI and to create treatment efficacy hierarchies we will conduct a network meta-analysis 
(NMA). NMA allows the efficacy comparison of interventions that do and do not have direct head-to-head comparison and allows 
generation of treatment hierarchies. Like conventional meta-analyses, NMAs also have tools to assess the heterogeneity and 
inaccuracy of efficacy estimates.    
 
Objectives 
 
The main objective of this project is to obtain all possible evidence for treatment of CDI and to summarize the efficacy hierarchy 
of treatments investigated so far.  
 
Study inclusion criteria 
 
Types of studies 
 
Randomised controlled trials, comparing at least two treatments for primary or recurrent CDI. Non-controlled, retrospective 
studies and studies, having fewer than 10 participants in total, will be excluded. Studies, comparing different dosing or delivery 
regimes of the same treatment modality without comparison with different treatment class, will be excluded. No language 
restrictions will be applied. Trials available only in abstract form or not reporting full patient numbers for intention-to-treat 
analysis will be excluded.  
 
Types of participants 
 
We included 18 year old and older patients with evidence of active Clostridium difficile associated diarrhoea. 
 
Inclusion criteria: 
 
18 year old and older patients 
Confirmed Clostridium difficile infection: 
 
1. Active diarrhoea AND 
2. Positive C difficile nucleic acid amplification test OR 
3. Positive C difficile cytotoxin assay result OR  
4. Stool culture growing C difficile OR 
5. Pseudomembranes seen on colonoscopy  
 
Exclusion criteria: 
 
No diarrhoea 
Multiple active treatments used simultaneously 
Multiply recurrent or multiply refractory CDI 
 
Types of interventions 
 
Studies investigating preventive therapies or multiple therapies in conjunction, will be excluded. Oral, intravenous 
pharmacological agents (antibiotics, resins, polymers, antibodies) or their enemas, probiotics, faecal microbiota transplant trials 
will be includedif they meet the criteria mentioned above.   
 
Any interventions meeting the above criteria will be included in the analysis regardless of their licensing state.  
 
Types of outcome measures 
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Primary outcome 
 
Sustained symptomatic cure, defined as resolution of diarrhea at the end of treatment period, no recurrence of diarrhoea and no 
requirement of further treatment and no death during the follow-up period 
 
Secondary outcomes 
 
Primary cure, defined as resolution of diarrhoea at the end of treatment period.  
Recurrence, defined as recurrence of diarhoea within the follow-up period after attainment of the primary cure.   
 
Searching strategies  
 
Electronic searches  
 
MEDLINE, EMBASE, Web of Knowledge, Cochrane Central Register of Controlled Trials (CENTRAL) will be searched since 
database inception using both plain and MeSH terms. No publication type and language restrictions will be applied. 
 
Searching other sources 
 
We will screen the reference lists of systematic reviews and/or meta-analyses published on CDI. We will search clinicaltrials.gov 
for all relevant trials and contact authors of important unpublished trials. We will also search the pharmaceutical company clinical 
trial databases for unpublished trials. 
 
Data collection and analysis  
 
Study selection 
 
Two authors will independently screen all titles and abstracts for full paper review. Any disagreements for full paper review will 
be resolved by consensus decision. In case, where multiple articles describe the same trial, only the most comprehensive 
description will be included.  
 
Data extraction 
 
Data from selected papers will be extracted by two authors independently in a predesigned table. Any disagreements will be 
resolved through discussion with the third author. The following data will be extracted:  
 
x First author name and year of publication 
x Trial registration number 
x Funding source 
x Investigated agents 
x Duration of follow-up 
x Geographical location 
x Definition of CDI severity 
x Definition of primary cure 
x Adjunctive therapy 
x Ethnicity of study participants 
x Patient characteristics in each study group (age, gender, duration of diarrhoea, % with previous CDI, % with severe CDI, 
% inpatient) 
x Total number of patients randomised in each arm 
x Outcome data: number of patients attaining a primary cure, number of patients experiencing a recurrence after primary 
cure. We will only use intention to treat results. 
 
Assessment of risk of bias  
 
Two authors will independently perform a critical appraisal of selected full studies. Cochrane risk of bias criteria will be used to 
evaluate the methodological quality of studies.2 The following domains will be assessed: random sequence generation, allocation 
concealment, blinding of participants and investigators, blinding of outcome assessment, incomplete outcome data (attrition bias), 
selective reporting (whether the most important outcomes have been reported).  
 
 
Data analysis 
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Intention to treat analysis will be used to summarise the individual study results. Any treatment discontinuation will be considered 
as failure. Random effects model will be utilised for pairwise comparison of two agents.  
 
Frequentist setting will be used to perform a network meta-analysis. 
 
Dichotomous outcomes will be expressed as odds ratio with 95% confidence interval. Cochrane Q statistic will be used to report 
the degree of statistical heterogeneity. Clinical heterogeneity will be assessed by analysing the patient groups and treatment 
regimes.  
 
Heterogeneity in network meta-analyses will be summarised by: 
x Cochrane Q statistic 
x Comparing direct and indirect evidence 
x Inconsistency plot 
 
Studies providing significant inconsistency will be removed in sensitivity analysis.  
 
R statistical software package µQHWPHWD¶ZLOOEHHPSOR\HGIRUVWDWLVWLFDODQDO\VHV3 
 
Sensitivity analyses 
 
We plan the follow sensitivity analyses: 
 
x Only blinded RCTs 
x Only trials published after 2000 
x Only trials with 50 or more patients in each investigation group 
x Only non-industry funded trials 
 
Subgroup analyses 
 
We plan the following subgroup analyses: 
 
x >65 versus <65 year old 
x Inpatient versus outpatient onset of CDI 
x Severe versus non-severe CDI 
x Initial versus non-initial CDI episode 
 
References 
1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-
associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant 
Staphylococcus aureus in community hospitals. Infection control and hospital epidemiology 2011; 32(4): 387-90. 
2. Higgins J. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The 
Cochrane Collaboration, 2011. http://training.cochrane.org/handbook  
3. 5FNHU*6FKZDU]HU*.UDKQ8.|QLJ-QHWPHWD1HWZRUN0HWD-Analysis using Frequentist Methods. R package 
version 0.8-0. 2015. http://cran.at.r-project.org/web/packages/netmeta/ 
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Appendix 2. Search strategy 
Ovid MEDLINE search 
 
1. "clostridium difficile"[MeSH Terms]  
2. "clostridium difficile"[All Fields]   
3. ³GLIILFLOH´>$OOWHUPs] 
4. ³&GLIILFLOH´>$OO)LHOGV@ 
5. ³FGLIILFLOH´>$OO)LHOGV@ 
6. ³(QWHURFROLWLVSVHXGRPHPEUDQRXV´>0H6+7HUPV@ 
7. ³SVHXGRPHPEUDQRXV´>$OO)LHOGV@ 
8. ³DQWLELRWLFGLDUUKRHD´>$OO)LHOGV@ 
9. ³DQWLELRWLFFROLWLV´>$OOILHOGV@ 
10. ³&',25&'$'´>$OO)LHOGV@ 
11. ³&ORVWULGLXPGLIILFLOH LQIHFWLRQV´>$OO)LHOGV@ 
12. ³&ORVWULGLXPGLIILFLOHDVVRFLDWHGGLDUUKRHD´>$OO)LHOGV@ 
13. 1 OR 2 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 
  
14. "anti-bacterial agents"[MeSH Terms]  
15. "anti-bacterial agents"[All Fields] 
16. "anti-bacterial"[All Fields] 
17. "antibiotic*"[All Fields]  
³9DQFRP\FLQRU0HWURQLGD]ROHRU)XVLGLFDFLGRU1LWD]R[DQLGHRU7HLFRSODQLQRU5LIDPSLFLQRU5LID[LPLQRU%DFLWUDFLQ
or Fidaxomicin or Amoxicillin or Azithromycin or Cephalosporin* or Cephalexin or Ciprofloxacin or Clarithromycin or 
Clindamycin or Doxycycline or Erythromycin or Flouroquinolone* or Levofloxacin or Macrolide* or Nitrofurantoin or 
Penicillin or Tetracycline or Trimethoprim or antibiotic* or Surotomycin or anti-bacterial* or anti bacterial* or antibacterial* 
or bacteriocid* or bactericid* or antimicrobial* or anti-microbial*) 
19. 14 OR 15 OR 16 OR 17 OR 18 
  
20. "styrenesulfonic acid polymer" [All Fields] 
³FKROHVW\UDPLQHUHVLQ´>0H6+7HUPV@ 
³&ROHVWLSRO¶>0H6+7HUPV@ 
³7ROHYDPHU25FROHVWLSRO25FKROHVW\UDPLQH´>$OOILHOGV@ 
24. 20 OR 21 OR 22 OR 23 
  
³)HFDOPLFURELRWDWUDQVSODQWDWLRQ´>0H6+7HUPV@ 
³)HFDOPLFURELRWDWUDQVSODQWDWLRQ´>$OOILHOGV@ 
³)HFDOPLFURELRWDWUDQVSODQW´>$OOILHOGV@ 
³)07´>$OOILHOGV@ 
³IHFDOWUDQVSODQW´[All fields] 
³IDHFDOWUDQVSODQW´>$OOILHOGV@ 
³PLFURELDO25PLFURELRWD$1'WUDQVSODQW´>$OOILHOGV@ 
32. 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 
  
³3URELRWLFV´>0H6+7HUPV@ 
³3URELRWLF´>$OOILHOGV@ 
³,PPXQRWKHUDS\´>0H6+7HUPV@ 
³LPPXQRJOREXOLQ25DQWLERG\25DQWLERGLHV25LPPXQRWKHUDS\´>$OOILHOGV@ 
37. 33 OR 34 OR 35 OR 36 
  
38. 20 OR 25 OR 32 OR 37 
   
39. 13 OR 38 
  
 
 
EMBASE (Ovid) search 
  
af=all fields 
1. clostridium difficile.af. 
2. Difficile.af. 
3. c difficile.af. 
4. pseudomembranous enterocolitis.af. 
5. Pseudomembranous.af. 
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6. antibiotic diarrhoea.af. 
7. antibiotic colitis.af. 
8. (CDI or CDAD).af. 
9. Clostridium difficile infections.af. 
10. Clostridium difficile associated diarrhoea.af. 
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
12. antiinfective agent.af.  
13. anti-bacterial agents.af.  
14. Anti-bacterial.af. 
15. Antibiotic*.af. 
16. (Vancomycin or Metronidazole or Fusidic acid or Nitazoxanide or Teicoplanin or Rifampicin or Rifaximin or Bacitracin 
or Fidaxomicin or Amoxicillin or Azithromycin or Cephalosporin* or Cephalexin or Ciprofloxacin or Clarithromycin or 
Clindamycin or Doxycycline or Erythromycin or Flouroquinolone* or Levofloxacin or Macrolide* or Nitrofurantoin or 
Penicillin or Tetracycline or Trimethoprim or antibiotic* or Surotomycin or anti-bacterial* or anti bacterial* or 
antibacterial* or bacteriocid* or bactericid* or antimicrobial* or anti-microbial*).af. 
17. 13 or 14 or 15 or 16 or 17 
18. styrenesulfonic acid polymer.af. 
19. cholestyramine resin.af. 
20. Colestipol.af.  
21. (Tolevamer or colestipol or cholestyramine).af. 
22. 19 or 20 or 21 or 22 
23. Fecal microbiota transplantation.af. 
24. Fecal microbiota transplant.af. 
25. FMT.af. 
26. fecal transplant.af. 
27. faecal transplant.af.  
28. ((microbial or microbiota) and transplant*).af. 
29. 24 or 25 or 26 or 27 or 28 or 29 
30. Probiotics.af. 
31. Probiotic.af.  
32. Immunotherapy.af.  
33. (immunoglobulin or antibody or antibodies or immunotherapy).af. 
34. 31 or 32 or 33 or 34 
35. 18 or 23 or 30 or 35 
36. 11 AND 35 
 
Web of Science search 
 
1. ts=clostridium difficile 
2. ts=Difficile 
3. ts=c difficile 
4. ts=pseudomembranous enterocolitis 
5. ts=Pseudomembranous 
6. ts=antibiotic diarrhoea 
7. ts=antibiotic colitis 
8. ts=(CDI or CDAD) 
9. ts=Clostridium difficile infections 
10. ts=Clostridium difficile associated diarrhoea 
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
12. ts=Anti-infective agent* 
13. ts=anti-bacterial agent* 
14. ts=Anti-bacterial 
15. ts=Antibiotic* 
16. ts=(Vancomycin or Metronidazole or Fusidic acid or Nitazoxanide or Teicoplanin or Rifampicin or Rifaximin or 
Bacitracin or Fidaxomicin or Amoxicillin or Azithromycin or Cephalosporin* or Cephalexin or Ciprofloxacin or 
Clarithromycin or Clindamycin or Doxycycline or Erythromycin or Flouroquinolone* or Levofloxacin or Macrolide* or 
Nitrofurantoin or Penicillin or Tetracycline or Trimethoprim or antibiotic* or Surotomycin or anti-bacterial* or anti 
bacterial* or antibacterial* or bacteriocid* or bactericid* or antimicrobial* or anti-microbial*) 
17. 13 or 14 or 15 or 16 or 17 
18. ts=styrenesulfonic acid polymer 
19. ts=cholestyramine resin 
20. ts=Colestipol  
21. ts=(Tolevamer or colestipol or cholestyramine) 
22. 19 or 20 or 21 or 22 
23. ts=Fecal microbiota transplantation 
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24. ts=Fecal microbiota transplant 
25. ts=FMT 
26. ts=fecal transplant 
27. ts=faecal transplant  
28. ts=((microbial or microbiota) and transplant*) 
29. 24 or 25 or 26 or 27 or 28 or 29 
30. ts=Probiotics 
31. ts=Probiotic  
32. ts=Immunotherapy  
33. ts=(immunoglobulin or antibody or antibodies or immunotherapy) 
34. 31 or 32 or 33 or 34 
35. 18 or 23 or 30 or 35 
36. 11 AND 35 
 
37. ts=randomized controlled trial 
38. ts=Trial 
39. ts=Longitudinal Stud* 
40. ts=Prospective Stud* 
41. ts=Random  
42. ts=Cohort Stud* 
43. ts=Prospective  
44. ts=Rct 
45. 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 
46. 12 and 36 and 45 
 
CENTRAL search 
  
ID Search  
#1 "Clostridium difficile"  (Word variations have been searched)  
#2 difficile   
#3 pseudomembranous   
#4 pseudomembranous enterocolitis   
#5 antibiotic diarrhoea   
#6 antibiotic colitis   
#7 CDI or CDAD   
#8 Clostridium difficile infection   
#9 Clostridium difficile associated diarrhoea   
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9   
#11 Antibiotics   
#12 antibiotic   
#13 antiinfective agent   
#14 anti-bacterial   
#15 (Vancomycin or Metronidazole or Fusidic acid or Nitazoxanide or Teicoplanin or Rifampicin or Rifaximin or 
Bacitracin or Fidaxomicin or Amoxicillin or Azithromycin or Cephalosporin* or Cephalexin or Ciprofloxacin or 
Clarithromycin or Clindamycin or Doxycycline or Erythromycin or Flouroquinolone* or Levofloxacin or Macrolide* or 
Nitrofurantoin or Penicillin or Tetracycline or Trimethoprim or antibiotic* or Surotomycin or anti-bacterial* or anti bacterial* 
or antibacterial* or bacteriocid* or bactericid* or antimicrobial* or anti-microbial*)   
#16 #11 or #12 or #13 or #14 or #15   
#17 "styrenesulfonic acid polymer"   
#18 "cholestyramine"   
#19 Colestipol   
#20 Tolevamer or colestipol or cholestyramine   
#21 #17 or #18 or #19 or #20   
#22 "Fecal Microbiota Transplantation"   
#23 Fecal microbiota transplant   
#24 FMT   
#25 fecal transplant   
#26 (microbial or microbiota) and transplant   
#27 #22 or #23 or #24 or #25 or #26   
#28 Probiotic   
#29 Probiotics   
#30 Immunotherapy   
#31 (immunoglobulin or antibody or antibodies or immunotherapy)   
#32 #28 or #29 or #30 or #31   
#33 #16 or #21 or #27 or #32   
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#34 #10 and #33   
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Appendix 3. Search flow diagrams 
 
 
 
 
  
 
10 
 
 
 
  
 
11 
 
12 
 
Appendix 4. Individual trial definitions of cure and CDI severity, participant ethnicity, prevalence of previous CDI and inpatients at onset 
Publication Definition of cure Definition of severity Ethnicity % with previous CDI episode 
% 
Inpatient 
at onset 
Zar 2007 Resolution of diarrhoea at day 6 and negative C difficile toxin in stool at days 6 and 10 
Patients with >2 points were considered to have severe CDAD. One 
point each was given for age >60 years, temperature >38ā3 C, 
albumin level <2ā5 mg/dL, or peripheral WBC count 115,000 
cells/mm3 within 48h of enrolment. Two points were given for 
endoscopic evidence of pseudomembranous colitis or treatment in 
the intensive care unit. 
N/A N/A N/A 
Wenisch 1996 
Lack of symptoms (no loose stools, gastrointestinal symptoms, or fever) 
and normalization of serum levels of C-reactive protein and leukocyte 
counts. 
Temperature, C-reactive protein, stool frequency and leukocyte count 
provided, but no severity criteria applied and patients were not 
categorized into separate severity categories. 
N/A N/A N/A 
Wullt 2004 Cessation of diarrhoea within 5±8 days of initiating treatment N/A N/A 0% 48% 
Young 1985 Resolution of diarrhoea was taken as the first day of <3 stools, provided that stool frequency did not again increase above twice a day. 
Stool frequency, duration of diarrhoea, fever, abdominal pain, and 
haemoglobin or albumin levels measured, but no severity criteria 
applied and patients were not categorized. 
N/A N/A N/A 
Vickers 2017 
Less than or equal to three unformed bowel movements in a 24-h period 
or less than 200 mLunformed stool in rectal collection devices at test of 
cure 
Modified European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID) criteria (non-severe vs severe). Severity 
categories were mild (<6 unformed bowel movements per day or 
ZKLWHEORRGFHOO>:%&@FRXQWȝ/PRGHUDWH±9 unformed 
bowel movements per day or WBC 12 001±ȝ/DQGVHYHUH
XQIRUPHGERZHOPRYHPHQWVSHUGD\RU:%&FRXQWV!
ȝ/ 
White 92%, 
African American 
4%, Native 
American 2 %, 
Multiple 2% 
13% 23% 
Louie 2011 
Resolution of diarrhoea (i.e., three or fewer unformed stools for 2 
consecutive days), with maintenance of resolution for the duration of 
therapy and no further requirement (in the investigDWRU¶VRSLQLRQIRU
therapy for C difficile infection as of the second day after the end of the 
course of therapy. 
Severity categories are defined as: Mild CDAD = 4-5 Unformed 
%0GD\25:%&PPñ; 
Moderate CDAD = 6-9 Unformed BM/day OR WBC 12,001-15,000 
PPñ; 6HYHUH&'$' 8QIRUPHG%0GD\25:%&
PPñ 
N/A 17% 59% 
Cornerly 2012 
Three or fewer unformed bowel movements per day for 2 days 
consecutively for the duration of treatment and no further need for 
treatment (decided by the investigator) as of  the second day after the last 
dose of study drug. 
To be classified as severe, had to meet one or more of European 
Society of Clinical Microbiology and Infectious Diseases criteria: 
!ZKLWHEORRGFHOOVSHUȝ/VHUXPFUeatinine concentration 
!āPJG/RUERG\WHPSHUDWXUH!ā& 
N/A 15% 68% 
Mullane 2015 
Resolution or improvement of the C difficile infection such that 
additional therapy was not needed. Patients considered to be clinically 
cured had to have had two consecutive days with an absence of severe 
abdominal pain or fever, as well as <3 non-liquid stools per day. 
Severe: > 10 unformed bowel movements per day or a white blood 
cell count of >15ā0  109 /liter 
93% Caucasian, 
5ā6% Black, 1ā3% 
Asian 
24% N/A 
Louie 2015 
The primary endpoint was clinical cure (defined as resolution of 
diarrhoea with no further CDI therapy required) as assessed by the 
investigator at a test-of-cure visit. Resolution of diarrhoea was defined as 
2 semi-formed or formed stools (types 1 to 4 on the Bristol Stool Chart) 
and no liquid or unformed stools for 2 consecutive 24h periods. 
Severe CDAD was defined as any one of the following: white blood 
cell count of 15,000/mm3, creatinine of 1ā5 mg, or core body 
temperature of  38ā& 
91% Caucasian 20% 18% 
Musher 2006 
Complete clinical response at the end of 7 days of 
treatment, defined as return of normal stool pattern and absence of fever, 
abdominal pain, or leukocytosis, unless some other explanation was 
apparent. 
Stool frequency, abdominal pain, presence of fever and white cell 
count provided, but no classification criteria used to classify patients 
into severe and non-severe CDI. 
77ā5% White, 
16ā9% Black, 
5ā6% Hispanic 
N/A 100% 
Musher 2009 
End-of-treatment response was defined as complete resolution of all 
symptoms and signs attributable to CDI during the 3 days after 
completion of therapy. 
Severe CDI was defined using a modification of the severity score 
recently described by Zar et al. 2007 (see above). One point each was 
assigned for age 60 years, 17 stools/day, temperature >38ā3  C, 
albumin level <2ā5 gm/dL, or WBC count >115,000 cells/mm3; a 
score of  >2 points was regarded as severe disease. 
69ā4% White, 
30ā6% Black N/A 86% 
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Dudley 1986 
Diarrhoea was considered resolved on the day of therapy on which less 
than four loose stools were passed during a 24-hour period for at least 
two consecutive days. 
N/A N/A N/A N/A 
Boix 2017 
Resolution of diarrhoHDLHORRVHVWRROVSHUKRXUVIRUFRQVHFXWLYH
days) and no need for additional CDI treatment after the trial treatment 
period. 
ESCMID Comprehensive Criteria, ESCMID Abbreviated Criteria, 
,'6$&ULWHULD8%0DQG:%&&ULWHULD+RUQ¶V,QGH[ 
89% White, 6ā5% 
Black or African, 
4ā7% 
Hispanic/Latino 
18% 63% 
Teasley 1983 
Patients were judged to be cured if their diarrhoea resolved within 6 
treatment days, they tolerated the complete treatment course, and they did 
not have a relapse of symptoms in the 21-day follow-up period 
N/A N/A N/A 100% 
Lee 2016 
Cure was defined as either resolution of diarrhoea (i.e. 
<4 unformed bowel movements LQDKSHULRGIRUFRQVHFXWLYHGD\V
sustained through 
2 days after last dose of study drug, and no additional antibiotics needed 
to treat the same CDI episode; or clinically significant improvement, such 
DVUHGXFWLRQLQ8%0VQRUPDOZKLWHEORRG cell count, normal body 
temperature and no additional antibiotics needed to treat the same CDI 
episode. Patients requiring a collection device were considered to have 
resolution of diarrhoea when the volume of stool (in 24 h) decreased by 
75% versus baseline or the patient was no longer passing liquid stool. 
Severe CDI was defined as the presence of pseudomembranous 
colitis documented by endoscopy; or being in the ICU at the time of 
randomisDWLRQRUGLDUUKRHDZLWKRIWKHIROORZLQJFULWHULDZKLWH
blood cell count >15000/mm3; albumin <2ā5 g/dL; aged >60 years; 
oral temperature >101ā8F or 38.3C 
89% White, 9% 
African American 17% N/A 
Louie 2006 The first day of 2 consecutive days when the patient had hard or formed 
stools (any number) or 2 stools of loose or watery consistency Severe defined as >12 stools in the 24h period preceding screening. 
91% White  7% 
Black, 1% 
Hispanic 
6% N/A 
Johnson 2014 
(301) 
Resolution of diarrhoea and absence of severe abdominal discomfort for 
more than 2 consecutive days including day 10. Resolution of diarrhoea 
was defined as attainment of bowel movements with a hard or formed 
consistency on average of 2 or fewer BM/day with a loose or watery 
consistency on average. 
CDI disease severity was categorized as mild (3-5 BM/day; white 
EORRGFHOOFRXQWV>:%&@PPPLOGRUDEVHQWDEGRPLQDO
pain due to CDI), moderate (6-9 BM/day; WBC 15,001 to 
20,000/mm3; mild, moderate, or absent abdominal pain due to CDI); 
RUVHYHUH%0GD\:%&PPVHYHUHDEGRPLQDOSDLQ
due to CDI). 
N/A 29% 56% 
Johnson 2014 
(302) Identical to Johnson 2014 (301) Identical to Johnson 2014 (301) N/A 17% 91% 
De Lalla 1992 The patients were considered clinically cured if they became 
asymptomatic (i.e., their symptoms and signs were eliminated). N/A N/A N/A 100% 
Thabit 2016 Normalization of stool consistency and reduction of stool frequency to less than three unformed stools per day by day 10 of therapy. N/A N/A N/A 50% 
NCT02179658 
2016 
(unpublished) 
µ&OLQLFDOFXUH¶rd Phase 3 trial for fidaxomicin versus vancomycin 
carried out by Astellas pharmaceuticals. It is reasonable to assume that 
the criteria for cure would be the same as in Louie 2011 and Cornely 
2012 trials. 
Not described. Might be reasonable to assume that the criteria the 
same as in Louie 2011 and Cornely 2012 trials for the same reasons.  
Japanese (% not 
given) 14% N/A 
Guery 2017 
µ&OLQLFDOFXUH¶,WLVD3KDVHESRVWPDUNHWLQJWULDODQGth RCT for 
fidaxomicin versus vancomycin carried out by Astellas pharmaceuticals. 
It is reasonable to assume that the criteria for cure would be the same as 
in Louie 2011 and Cornely 2012 trials. 
Not described. Might be reasonable to assume that the criteria the 
same as in Louie 2011 and Cornely 2012 trials for the same reasons. 100% White N/A N/A 
Pardi 2012  
(unpublished) 
< 3 unformed stools/day for 2 consecutive days at test-of-cure visit 14 
days after initiation of treatment N/A 
88% White, 12% 
Non-white N/A N/A 
Mitra 2017 
(unpublished) 
Not described. But Phase 2 trial (Vickers et al.) published earlier in the 
year by the same team. Criteria, likely, the same. 
Modified ESCMID comprehensive criteria 
 
N/A N/A N/A 
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Appendix 5. Support for judgements in risk of bias assessments 
Author, Year Cochrane RoB criteria Judgement (1 - low, 2 - 
unclear, 3 - high) Supporting comment 
Zar 2007 Randomisation 2 A pharmacist picked up a card in the sealed envelope, but no mention of how random sequence was generated 
  Allocation Concealment 1 Drug cards drawn from sealed envelopes.  
  Blinding of participants and personnel 1 Similar looking tablets used for metronidazole and similar liquid for vancomycin 
  Blinding of outcome assessment 2 No mention 
  Incomplete outcome data 1 22/172 (12ā8%) patients dropped out before completion of treatment. Although reasons for the dropout explained, only per protocol analysis performed. Patients, who died during treatment, were excluded from analysis, but balance between groups maintained and death causes similar.  
  Selective reporting 1 All main outcomes reported 
Wenisch 1996 Randomisation 1 Table of random numbers used 
  Allocation Concealment 2 No mention of allocation concealment used 
  Blinding of participants and personnel 3 Not blinded 
  Blinding of outcome assessment 3 Not blinded 
  Incomplete outcome data 2 126 randomised, but 3 died and 4 excluded - not mentioned which group these patients were randomised to and per protocol analysis performed. Unclear if these could have affected the outcomes. 
  Selective reporting 1 All main outcomes reported 
Wullt 2004 Randomisation 1 Statistician generated a set of random numbers 
  Allocation Concealment 1 Medications provided in coded blister packs 
  Blinding of participants and personnel 1 Quote "The placebo capsules and tablets did not differ in form or colour from the active counterparts" 
  Blinding of outcome assessment 2 Investigator team was unaware of treatment arms through the identical looking treatment packs, but not clear whether blinded to outcome 
  Incomplete outcome data 3 Total of 131 randomised, 20 lost from fusidic acid and 14 from metronidazole arms. High percentage and imbalanced attrition 
  Selective reporting 1 All main outcomes reported 
Young 1985 Randomisation 2 Sequence generated in random fashion, unclear how 
  Allocation Concealment 1 Packages coded by independent physician 
  Blinding of participants and personnel 1 Identical looking red capsules 
  Blinding of outcome assessment 2 Not mentioned whether assessors were blinded as well 
  Incomplete outcome data 1 No dropouts 
  Selective reporting 1 All main outcomes reported 
Vickers 2017 Randomisation 1 External stratified computer randomisation 
  Allocation Concealment 1 Quote "Randomisation and study group assignment was done by an interactive voice and web response system (IVRS/IWRS)" 
  Blinding of participants and personnel 1 Quote "Blinding was achieved by over-encapsulation of both study drugs (ridinidazole and vancomycin) and a placebo within identical size zero, Swedish orange, hard gelatine immediate-release capsules" 
15 
 
  Blinding of outcome assessment 1 Investigators and assessors blind until database lock 
  Incomplete outcome data 1 Dropouts present but equal between groups 
  Selective reporting 1 All main outcomes reported as provided in the registration protocol 
Louie 2011 Randomisation 1 Computerised randomisation with stratification regarding primary/recurrent status 
  Allocation Concealment 1 Interactive voice response system used to allocate the treatment package code 
  Blinding of participants and personnel 1 Overencapsulated original capsules looked the same 
  Blinding of outcome assessment 1 Randomisation schedule not revealed to investigators or assessors 
  Incomplete outcome data 1 13% patients lost from both groups - balanced with balanced underlying reasons 
  Selective reporting 1 All main outcomes reported as provided in the registration protocol 
Cornely 2012 Randomisation 1 Computer generated randomisation schedule 
  Allocation Concealment 1 Interactive voice response system used to allocate the treatment package code 
  Blinding of participants and personnel 1 Overencapsulated original capsules looked the same 
  Blinding of outcome assessment 1 Everyone blinded until database lock, then only statisticians non-blinded 
  Incomplete outcome data 1 <10% dropout. Slightly more people discontinued treatment early in fidaxomicin group due to early cure compared to vancomycin. 
  Selective reporting 1 All main outcomes reported as provided in the registration protocol 
Mullane 2015 Randomisation 2 Not mentioned how random sequence was generated. Only described that randomisation cards drawn at every centre. At baseline groups differed in 
age and previous therapy 
  Allocation Concealment 2 Site specific randomisation cards, but no further details 
  Blinding of participants and personnel 3 No blinding mentioned 
  Blinding of outcome assessment 2 Evaluator blind, but not explained how 
  Incomplete outcome data 3 14/46 in LFF571 group and 2/26 in vancomycin group withdrew from the study 
  Selective reporting 1 All main outcomes reported 
Louie 2015 Randomisation 1 Computer generated, as interactive voice system used for allocation 
  Allocation Concealment 1 Interactive voice response system  
  Blinding of participants and personnel 1 Cadazolid and vancomycin had indistinguishable placebo 
  Blinding of outcome assessment 2 Double-blind, but no mention of assessor blinding 
  Incomplete outcome data 1 4/62 in Cadazolid and 1/22 in Vancomycin did not finish study - similar numbers 
  Selective reporting 1 All main outcomes reported 
Musher 2006 Randomisation 2 Randomised trial, but method for randomisation sequence not mentioned 
  Allocation Concealment 2 No mention 
  Blinding of participants and personnel 2 Double-blind, but no mention of blinding method 
  Blinding of outcome assessment 2 Method not described 
  Incomplete outcome data 3 10/44 in Metronidazole and 22/98 in nitazoxanide group did not complete treatment. This is >20% 
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  Selective reporting 1 All main outcomes reported 
Musher 2009 Randomisation 2 Randomised, but random sequence generation method not described 
  Allocation Concealment 1 Quote "each site sequentially assigned each patient a number from its allotment of blinded study medication.  The  randomisation  code  was sealed  
and  maintained  in  the  files  of  the  study  sponsor" 
  Blinding of participants and personnel 1 Dummy placebo pill identical to nitazoxanide or vancomycin 
  Blinding of outcome assessment 1 Investigators blind to study allocation by medication code until database lock 
  Incomplete outcome data 1 4 patients lost from both arms - balanced. 8/50 dropouts in total 
  Selective reporting 1 All main outcomes reported 
Dudley 1986 Randomisation 1 Random number table 
  Allocation Concealment 2 Not described 
  Blinding of participants and personnel 2 Vancomycin and bacitracin aliquots prepared by pharmacist, but no mention whether they looked the same.  
  Blinding of outcome assessment 2 Coded treatment bottles in pharmacy, but not clear whether assessor was blind.  
  Incomplete outcome data 3 Per protocol analysis only. Out of 62 enrolled, only 30 evaluated. High dropout due to non-confirmed C difficile infection at randomisation 
  Selective reporting 1 All main outcomes reported 
Boix 2017 Randomisation 1 Centralised stratified computer-randomisation  
  Allocation Concealment 1 Interactive voice system for allocation withy codes held centrally 
  Blinding of participants and personnel 1 Alternative dummy tablets of active comparator 
  Blinding of outcome assessment 1 Investigators blind until study database lock. Adequate allocation concealment and patient /personnel blinding 
  Incomplete outcome data 2 54/298 (18%) in vancomycin group and 68/308 (22%) in suratomycin group dropped out 
  Selective reporting 1 All main outcomes reported 
Teasley 1983 Randomisation 1 Random number table 
  Allocation Concealment 3 Not described and no blinding mentioned 
  Blinding of participants and personnel 3 No blinding 
  Blinding of outcome assessment 3 No blinding 
  Incomplete outcome data 1 7 dropouts. Equally distributed and explained 
  Selective reporting 1 All main outcomes reported 
Lee 2016 Randomisation 1 Centralised stratified computer-randomisation  
  Allocation Concealment 1 Interactive voice system used 
  Blinding of participants and personnel 1 Single dummy 
  Blinding of outcome assessment 1 Each patient coded, blinding maintained until the study end 
  Incomplete outcome data 1 8/139 in suratomycin group and 63/70 in vancomycin group dropped out 
  Selective reporting 1 All main outcomes reported 
Louie 2006 Randomisation 2 Sequence generation not described 
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  Allocation Concealment 2 Not described 
  Blinding of participants and personnel 1 Study named as "double-blind". Matching placebo used 
  Blinding of outcome assessment 2 Double-blind, but not clear if assessor blinded 
  Incomplete outcome data 3 High attrition: 43/185 in tolevamer, 14/94 in vancomycin groups. Not balanced 
  Selective reporting 1 All main outcomes reported 
Johnson 2014 
(301&302 ± 
identical 
design) 
  
  
  
  
  
Randomisation 2 Quote "Randomization was conducted using a centralized, blocked scheme". No mention of how sequence was generated 
Allocation Concealment 2 Not described 
Blinding of participants and personnel 1 Double-dummy 
Blinding of outcome assessment 2 Blinding maintained until database lock. 
Incomplete outcome data 2 Did not complete follow-up: 101/563 in tolevamer, 36/266 in Vancomycin, 49/289 in Metronidazole group. 
Selective reporting 1 All main outcomes reported 
De Lalla 1992 Randomisation 2 Sequence generation not described 
  Allocation Concealment 2 Not described 
  Blinding of participants and personnel 3 No blinding 
  Blinding of outcome assessment 3 No blinding 
  Incomplete outcome data 1 Drop-outs: 4/24 in vancomycin and 1/27 in teicoplanin group 
  Selective reporting 1 All main outcomes reported 
Thabit 2016 Randomisation 2 Randomisation sequence generation not described 
  Allocation Concealment 2 Not described 
  Blinding of participants and personnel 3 Open label study 
  Blinding of outcome assessment 3 Open label study 
  Incomplete outcome data 2 Drop outs: 1/7 in fidaxomicin and 1/5 in vancomycin group 
  Selective reporting 1 All main outcomes reported 
NCT02179658 
2016 
(unpublished) 
  
  
  
  
  
Randomisation 2 Randomised trial, but method for randomisation sequence not mentioned 
Allocation Concealment 2 Not described 
Blinding of participants and personnel 1 Double-dummy with fidaxomicin and vancomicin placebos looking identical 
Blinding of outcome assessment 1 Evaluator kept blind of which medication patient has been assigned by double-dummy blinding. 
Incomplete outcome data 2 92/106 in FID and 80/109 in VAN group finished antibiotic course. Reasons for drop out - side effects. Dropouts explained, higher in vancomycin group but exceeds 20% 
Selective reporting 1 All main outcomes reported 
Guery 2017 
 
  
  
Randomisation 2 Randomised trial, but method for randomisation sequence not mentioned 
Allocation Concealment 2 Not described 
Blinding of participants and personnel 3 Open label study 
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Blinding of outcome assessment 3 Open label study 
Incomplete outcome data 2 51/183 in fidoxamicin and 56/181 in vancomycin arms discontinued study. Balanced, but high percentage of discontinuation, though study follow-up 
of 90 days is long. 
Selective reporting 1 All main outcomes reported 
Pardi 2012 
(unpublished) 
  
  
  
  
  
Randomisation 1 Random permuted blocks used to generate a randomisation sequence 
Allocation Concealment 1 The numbered list of treatment sequence assignments will be provided by a central call-in phone number 
Blinding of participants and personnel 1 Identical appearing placebo tablets to vancomycin and rifaximin 
Blinding of outcome assessment 2 Patients coded with an assignment number, but blinding of outcome assessors not clear 
Incomplete outcome data 3 High attrition: 41/119 in rifaximin and 27/119 in vancomycin group discontinued trial. Attrition markedly higher in rifaximin group. Reasons: treatment failure and adverse events 
Selective reporting 1 All main outcomes reported 
Mitra 2017 Randomisation 2 Randomised trial, but method for randomisation sequence not mentioned 
  Allocation Concealment 2 Not described 
  Blinding of participants and personnel 3 Open label study 
  Blinding of outcome assessment 3 Open label study 
  Incomplete outcome data 1 No dropouts 
  Selective reporting 1 All main outcomes reported 
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Appendix 6. Cumulative risk of bias table 
  
20 
 
 
Appendix 7. Sustained symptomatic cure. Vancomycin as reference 
a) Forest plot 
 
 
 
b) Heatmap to identify points of single design heterogeneity 
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c) Heterogeneity and decomposition of Cochrane Q score in within and between designs  
components 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0; I^2 = 0% 
 
Q statistics to assess homogeneity / consistency 
 
                      Q df p-value 
Total  15.80 16 0.4673 
Within designs  12.61 9 0.1813 
Between designs 3.19 7 0.8669 
 
Design-specific decomposition of within-designs Q statistic 
 
Design  Q  df   p-value 
VAN:BAC  0ā48 1    0ā4898 
VAN:FID  2ā66 4    0ā6168 
VAN:MET  3ā94 1    0ā0470 
VAN:SUR  2ā23 1    0ā1358 
VAN:MET:TOL3ā30 2    0ā1918 
 
Between-designs Q statistic after detaching of single designs 
 
Detached design Q df p-value 
FID:RID  3ā19 6 0ā7847 
FUA:MET  1ā11 6 0ā9810 
MET:NIT  3ā17 6 0ā7868 
VAN:FID  3ā19 6 0ā7847 
VAN:MET  3ā19 6 0ā7846 
VAN:NIT  3ā17 6 0ā7868 
VAN:RID  3ā19 6 0ā7847 
VAN:TEIC  3ā18 6 0ā7861 
VAN:TOL  2ā46 6 0ā8732 
VAN:FUA:MET:TEIC 0ā77 4 0ā9429 
VAN:MET:TOL 2ā44 5 0ā7857 
 
Q statistic to assess consistency under the assumption of 
a full design-by-treatment interaction random effects model 
 
   Q df p-value tau.within tau2.within 
Between designs 2ā74 7 0ā9084 0ā1616 0ā0261 
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Appendix 8. Primary cure rate. Vancomycin as reference 
 
a)  League table 
 
0ā8732             
TEIC 0ā6895            
0ā55 [0ā11; 
2ā64] FUA 0ā6712           
0ā53 [0ā11; 
2ā61] 
0ā96 [0ā29; 
3ā14] RID 0ā6229          
0ā46 [0ā11; 
1ā83] 
0ā83 [0ā35; 
2ā00] 
0ā87 [0ā39; 
1ā93] VAN 0ā6228         
0ā48 [0ā10; 
2ā19] 
0ā87 [0ā30; 
2ā55] 
0ā91 [0ā33; 
2ā50] 
1ā05 [0ā57; 
1ā95] RFX 0ā5554        
0ā45 [0ā08; 
2ā54] 
0ā81 [0ā21; 
3ā18] 
0ā85 [0ā23; 
3ā16] 
0ā98 [0ā35; 
2ā78] 
0ā93 [0ā28; 
3ā14] CAD 0ā5400       
0ā43 [0ā09; 
2ā00] 
0ā78 [0ā27; 
2ā26] 
0ā82 [0ā29; 
2ā34] 
0ā94 [0ā48; 
1ā87] 
0ā90 [0ā36; 
2ā26] 
0ā96 [0ā28; 
3ā35] NIT 0ā5217      
0ā42 [0ā10; 
1ā72] 
0ā77 [0ā31; 
1ā90] 
0ā80 [0ā35; 
1ā82] 
0ā92 [0ā73; 
1ā17] 
0ā88 [0ā45; 
1ā71] 
0ā94 [0ā32; 
2ā75] 
0ā98 [0ā48; 
2ā02] FID 0ā4311     
0ā38 [0ā09; 
1ā60] 
0ā70 [0ā27; 
1ā79] 
0ā73 [0ā31; 
1ā74] 
0ā84 [0ā60; 
1ā18] 
0ā80 [0ā40; 
1ā63] 
0ā86 [0ā29; 
2ā58] 
0ā89 [0ā42; 
1ā91] 
0ā91 [0ā60; 
1ā38] SUR 0ā4055    
0ā35 [0ā06; 
1ā94] 
0ā63 [0ā16; 
2ā43] 
0ā66 [0ā18; 
2ā41] 
0ā76 [0ā27; 
2ā11] 
0ā72 [0ā22; 
2ā39] 
0ā77 [0ā18; 
3ā34] 
0ā80 [0ā23; 
2ā75] 
0ā82 [0ā29; 
2ā35] 
0ā90 [0ā31; 
2ā65] LFF571 0ā2839   
0ā29 [0ā06; 
1ā46] 
0ā52 [0ā15; 
1ā77] 
0ā55 [0ā17; 
1ā75] 
0ā63 [0ā27; 
1ā47] 
0ā60 [0ā21; 
1ā72] 
0ā64 [0ā17; 
2ā47] 
0ā67 [0ā22; 
1ā98] 
0ā68 [0ā28; 
1ā65] 
0ā75 [0ā30; 
1ā87] 
0ā83 [0ā22; 
3ā15] BAC 0ā2797  
0ā33 [0ā08; 
1ā33] 
0ā60 [0ā26; 
1ā38] 
0ā62 [0ā26; 
1ā46] 
0ā72 [0ā53; 
0ā97] 
0ā68 [0ā34; 
1ā36] 
0ā73 [0ā25; 
2ā16] 
0ā76 [0ā40; 
1ā45] 
0ā78 [0ā53; 
1ā14] 
0ā85 [0ā54; 
1ā34] 
0ā95 [0ā32; 
2ā75] 
1ā14 [0ā46; 
2ā80] MET 0ā0030 
0ā11 [0ā03; 
0ā44] 
0ā20 [0ā08; 
0ā47] 
0ā20 [0ā09; 
0ā47] 
0ā23 [0ā18; 
0ā31] 
0ā22 [0ā11; 
0ā44] 
0ā24 [0ā08; 
0ā70] 
0ā25 [0ā12; 
0ā50] 
0ā25 [0ā18; 
0ā36] 
0ā28 [0ā18; 
0ā43] 
0ā31 [0ā11; 
0ā90] 
0ā37 [0ā15; 
0ā91] 
0ā33 [0ā25; 
0ā43] TOL 
 
League table of pairwise comparisons in network meta-analysis for attaining a primary symptomatic cure. Treatments 
order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which are used to rank the 
treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant pairwise comparisons are 
highlighted. BAC ± bacitracin, CAD - cadazolid, FID - fidaxomicin, FUA ± fusidic acid, MET ± metronidazole, NIT ± 
nitazoxanide, RFX ± rifaximin, RID ± ridinidazole, SUR ± suratomycin, TEIC ± teicoplanin, TOL ± tolevamer, VAN ± 
vancomycin. 
b) Forest plot 
 
 
 
 
 
 
 
 
 
 
 
c)   Heterogeneity and decomposition of Cochrane Q score in within and between designs components 
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Quantifying heterogeneity / inconsistency: 
tau^2 = 0; I^2 = 0% 
 
Q statistics to assess homogeneity / consistency 
 
  Q df p-value 
Total  13ā52 16 0ā6343 
Within designs 6ā60 9 0ā6789 
Between designs 6ā92 7 0ā4369 
 
Design-specific decomposition of within-designs Q statistic 
 
Design  Q df p-value 
VAN:BAC 0ā06 1 0ā8072 
 VAN:FID  3ā67 4 0ā4524 
 VAN:MET 1ā47 1 0ā2249 
 VAN:SUR 0ā56 1 0ā4561 
 VAN:MET:TOL 0ā84 2 0ā6572 
 
Between-designs Q statistic after detaching of single designs 
 
Detached design Q df p-value 
FID:RID  5ā27 6 0ā5091 
FUA:MET  6ā69 6 0ā3500 
MET:NIT  6ā92 6 0ā3288 
VAN:FID  5ā27 6 0ā5091 
VAN:MET 6ā90 6 0ā3306 
VAN:NIT  6ā92 6 0ā3288 
VAN:RID  5ā27 6 0ā5091 
VAN:TEIC 6ā87 6 0ā3328 
VAN:TOL  2ā25 6 0ā8949 
VAN:FUA:MET:TEIC6ā49 4 0ā1652 
 VAN:MET:TOL 2ā10 5 0ā8345 
 
Q statistic to assess consistency under the assumption of 
a full design-by-treatment interaction random effects model 
 
  Q df  p-value tau.within tau2.within 
Between designs 6.92 7 0.4369 0 0 
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Appendix 9. Recurrence rate. Vancomycin as reference 
 
a) League table 
 
0ā8835             
TOL 0ā7965            
1ā25 [0ā65; 
2ā40] FID 0ā7964           
1ā09 [0ā29; 
4ā13] 
0ā88 [0ā24; 
3ā25] TEIC 0ā7344          
1ā32 [0ā39; 
4ā50] 
1ā06 [0ā34; 
3ā30] 
1ā20 [0ā23; 
6ā40] RID 0ā5699         
1ā97 [0ā93; 
4ā21] 
1ā58 [0ā80; 
3ā14] 
1ā81 [0ā46; 
7ā05] 
1ā50 [0ā43; 
5ā20] SUR 0ā5661        
1ā91 [0ā52; 
6ā97] 
1ā53 [0ā44; 
5ā36] 
1ā75 [0ā31; 
9ā75] 
1ā45 [0ā29; 
7ā38] 
0ā97 [0ā26; 
3ā58] CAD 0ā4330       
2ā53 [0ā82; 
7ā82] 
2ā03 [0ā65; 
6ā34] 
2ā32 [0ā47; 
11ā45] 
1ā92 [0ā41; 
8ā98] 
1ā28 [0ā39; 
4ā26] 
1ā33 [0ā27; 
6ā52] NIT 0ā3928      
2ā77 [0ā73; 
10ā56] 
2ā22 [0ā61; 
8ā13] 
2ā53 [0ā44; 
14ā61] 
2ā10 [0ā40; 
11ā09] 
1ā40 [0ā36; 
5ā42] 
1ā45 [0ā26; 
8ā02] 
1ā09 [0ā21; 
5ā57] LFF571 0ā3497     
2ā89 [1ā72; 
4ā85] 
2ā32 [1ā55; 
3ā47] 
2ā64 [0ā76; 
9ā17] 
2ā19 [0ā72; 
6ā68] 
1ā46 [0ā84; 
2ā54] 
1ā51 [0ā46; 
4ā95] 
1ā14 [0ā39; 
3ā30] 
1ā04 [0ā30; 
3ā59] VAN 0ā3068    
3ā30 [0ā97; 
11ā17] 
2ā65 [0ā82; 
8ā58] 
3ā02 [0ā57; 
15ā94] 
2ā51 [0ā52; 
12ā03] 
1ā67 [0ā49; 
5ā75] 
1ā73 [0ā34; 
8ā73] 
1ā30 [0ā28; 
6ā03] 
1ā19 [0ā23; 
6ā25] 
1ā14 [0ā38; 
3ā45] BAC 0ā2587   
3ā36 [1ā89; 
5ā97] 
2ā69 [1ā46; 
4ā98] 
3ā07 [0ā86; 
10ā93] 
2ā55 [0ā76; 
8ā52] 
1ā70 [0ā83; 
3ā50] 
1ā76 [0ā49; 
6ā28] 
1ā32 [0ā49; 
3ā56] 
1ā21 [0ā32; 
4ā53] 
1ā16 [0ā73; 
1ā85] 
1ā02 [0ā31; 
3ā37] MET 0ā2175  
4ā08 [1ā20; 
13ā94] 
3ā27 [1ā00; 
10ā70] 
3ā73 [0ā70; 
19ā83] 
3ā10 [0ā64; 
14ā98] 
2ā07 [0ā60; 
7ā17] 
2ā14 [0ā42; 
10ā87] 
1ā61 [0ā35; 
7ā51] 
1ā48 [0ā28; 
7ā78] 
1ā41 [0ā46; 
4ā30] 
1ā24 [0ā26; 
5ā94] 
1ā22 [0ā36; 
4ā06] RFX 0ā1947 
4ā01 [1ā59; 
10ā11] 
3ā22 [1ā27; 
8ā16] 
3ā67 [0ā93; 
14ā41] 
3ā05 [0ā76; 
12ā28] 
2ā03 [0ā74; 
5ā55] 
2ā10 [0ā49; 
8ā97] 
1ā58 [0ā45; 
5ā51] 
1ā45 [0ā33; 
6ā45] 
1ā39 [0ā60; 
3ā21] 
1ā22 [0ā30; 
4ā87] 
1ā20 [0ā55; 
2ā58] 
0ā98 [0ā24; 
3ā96] FUA 
 
League table of pairwise comparisons in network meta-analysis for recurrence. Treatments order in the rank 
of their chance of being the best treatment. Higher numbers in grey boxes are P-Scores, which are used to rank the treatments, 
mean lower chance of getting recurrence. Treatment estimates are provided as odds ratios with 95% confidence intervals. 
Significant pairwise comparisons are highlighted. BAC ± bacitracin, CAD - cadazolid, FID - fidaxomicin, FUA ± fusidic acid, 
MET ± metronidazole, NIT ± nitazoxanide, RFX ± rifaximin, RID ± ridinidazole, SUR ± suratomycin, TEIC ± teicoplanin, TOL ± 
tolevamer, VAN ± vancomycin. 
b) Forest plot 
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c) Heterogeneity and decomposition of Cochrane Q score into within and between designs components 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0ā0885; I^2 = 33ā4% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
  Q d.f. p-value 
Total  24ā02 16 0ā0891 
Within designs 10ā99 9 0ā2761 
Between designs 13ā02 7 0ā0715 
 
Design-specific decomposition of within-designs Q statistic 
 
Design Q df  p-value 
VAN:BAC 0ā63 1 0ā4284 
VAN:FID 6ā31 4 0ā1768 
VAN:MET 2ā11 1 0ā1466 
VAN:SUR 0ā66 1 0ā4180 
VAN:MET:TOL 1ā29 2 0ā5249 
 
Between-designs Q statistic after detaching of single designs 
 
Detached design  Q df p-value 
FID:RID  10ā93 6 0ā0905 
FUA:MET  11ā79 6 0ā0669 
MET:NIT  12ā87 6 0ā0451 
VAN:FID  10ā93 6 0ā0905 
VAN:MET  12ā97 6 0ā0434 
VAN:NIT  12ā87 6 0ā0451 
VAN:RID  10ā93 6 0ā0905 
VAN:TEIC  13ā01 6 0ā0428 
VAN:TOL  3ā68 6 0ā7205 
VAN:FUA:MET:TEIC 11ā75 4 0ā0193 
VAN:MET:TOL  3ā55 5 0ā6165 
 
Q statistic to assess consistency under the assumption of 
a full design-by-treatment interaction random effects model 
 
   Q df p-value tau.within tau2.within 
Between designs  10ā99 7 0ā1388 0ā1709 0ā0292 
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Appendix 10. Scatter plot 
 
Scatter plot. Chance of being the best in primary cure versus having the lowest recurrence rate 
X axis ± P-score for being the best treatment in attaning a primary cure; Y axis ± P-score for having the lowest chance of 
recurrence. BAC ± bacitracin, CAD - cadazolid, FID - fidaxomicin, FUA ± fusidic acid, MET ± metronidazole, NIT ± 
nitazoxanide, RFX ± rifaximin, RID ± ridinidazole, SUR ± suratomycin, TEIC ± teicoplanin, TOL ± tolevamer, VAN ± 
vancomycin. 
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Appendix 11ā Direct versus indirect evidence for sustained symptomatic cure 
 
 Random effects model 
comparison K prop nma direct indirā RoR z p-value 
BAC:CAD 0 0 2ā41 ā 2ā41 ā ā ā 
BAC:FID 0 0 2ā48 ā 2ā48 ā ā ā 
BAC:FUA 0 0 1ā42 ā 1ā42 ā ā ā 
BAC:LFF571 0 0 1ā33 ā 1ā33 ā ā ā 
BAC:MET 0 0 1ā22 ā 1ā22 ā ā ā 
BAC:NIT 0 0 1ā78 ā 1ā78 ā ā ā 
BAC:RFX 0 0 1ā53 ā 1ā53 ā ā ā 
BAC:RID 0 0 2ā94 ā 2ā94 ā ā ā 
BAC:SUR 0 0 1ā85 ā 1ā85 ā ā ā 
BAC:TEIC 0 0 4ā53 ā 4ā53 ā ā ā 
BAC:TOL 0 0 0ā67 ā 0ā67 ā ā ā 
BAC:VAN 2 1 1ā66 1ā66 ā ā ā ā 
CAD:FID 0 0 1ā03 ā 1ā03 ā ā ā 
CAD:FUA 0 0 0ā59 ā 0ā59 ā ā ā 
CAD:LFF571 0 0 0ā55 ā 0ā55 ā ā ā 
CAD:MET 0 0 0ā51 ā 0ā51 ā ā ā 
CAD:NIT 0 0 0ā74 ā 0ā74 ā ā ā 
CAD:RFX 0 0 0ā64 ā 0ā64 ā ā ā 
CAD:RID 0 0 1ā22 ā 1ā22 ā ā ā 
CAD:SUR 0 0 0ā77 ā 0ā77 ā ā ā 
CAD:TEIC 0 0 1ā88 ā 1ā88 ā ā ā 
CAD:TOL 0 0 0ā28 ā 0ā28 ā ā ā 
CAD:VAN 1 1 0ā69 0ā69 ā ā ā ā 
FID:FUA 0 0 0ā57 ā 0ā57 ā ā ā 
FID:LFF571 0 0 0ā54 ā 0ā54 ā ā ā 
FID:MET 0 0 0ā49 ā 0ā49 ā ā ā 
FID:NIT 0 0 0ā72 ā 0ā72 ā ā ā 
FID:RFX 0 0 0ā62 ā 0ā62 ā ā ā 
FID:RID 1 0ā23 1ā19 1ā17 1ā19 -0ā98 0ā03 0ā9790 
FID:SUR 0 0 0ā75 ā 0ā75 ā ā ā 
FID:TEIC 0 0 1ā83 ā 1ā83 ā ā ā 
FID:TOL 0 0 0ā27 ā 0ā27 ā ā ā 
FID:VAN 5 0ā99 0ā67 0ā67 0ā66 1ā02 0ā03 0ā9791 
FUA:LFF571 0 0 0ā94 ā 0ā94 ā ā ā 
FUA:MET 2 0ā9 0ā86 0ā84 0ā97 -0ā87 0ā15 0ā8826 
FUA:NIT 0 0 1ā25 ā 1ā25 ā ā ā 
FUA:RFX 0 0 1ā08 ā 1ā08 ā ā ā 
FUA:RID 0 0 2ā07 ā 2ā07 ā ā ā 
FUA:SUR 0 0 1ā3 ā 1ā3 ā ā ā 
FUA:TEIC 1 0ā54 3ā19 4ā39 2ā19 2ā01 0ā65 0ā5161 
FUA:TOL 0 0 0ā47 ā 0ā47 ā ā ā 
FUA:VAN 1 0ā28 1ā17 1ā8 0ā99 1ā83 0ā88 0ā3788 
LFF571:MET 0 0 0ā92 ā 0ā92 ā ā ā 
LFF571:NIT 0 0 1ā34 ā 1ā34 ā ā ā 
LFF571:RFX 0 0 1ā15 ā 1ā15 ā ā ā 
LFF571:RID 0 0 2ā21 ā 2ā21 ā ā ā 
LFF571:SUR 0 0 1ā39 ā 1ā39 ā ā ā 
LFF571:TEIC 0 0 3ā41 ā 3ā41 ā ā ā 
LFF571:TOL 0 0 0ā5 ā 0ā5 ā ā ā 
LFF571:VAN 1 1 1ā25 1ā25 ā ā ā ā 
MET:NIT 1 0ā75 1ā46 1ā43 1ā57 -0ā91 0ā13 0ā8976 
MET:RFX 0 0 1ā26 ā 1ā26 ā ā ā 
MET:RID 0 0 2ā42 ā 2ā42 ā ā ā 
MET:SUR 0 0 1ā52 ā 1ā52 ā ā ā 
MET:TEIC 1 0ā43 3ā72 2ā43 5ā12 -0ā47 0ā75 0ā4504 
MET:TOL 2 0ā83 0ā55 0ā54 0ā62 -0ā87 0ā39 0ā6973 
MET:VAN 5 0ā88 1ā37 1ā39 1ā21 1ā14 0ā33 0ā7448 
NIT:RFX 0 0 0ā86 ā 0ā86 ā ā ā 
NIT:RID 0 0 1ā65 ā 1ā65 ā ā ā 
NIT:SUR 0 0 1ā04 ā 1ā04 ā ā ā 
NIT:TEIC 0 0 2ā55 ā 2ā55 ā ā ā 
NIT:TOL 0 0 0ā38 ā 0ā38 ā ā ā 
NIT:VAN 1 0ā29 0ā93 0ā88 0ā96 -0ā91 0ā13 0ā8976 
RFX:RID 0 0 1ā92 ā 1ā92 ā ā ā 
RFX:SUR 0 0 1ā21 ā 1ā21 ā ā ā 
RFX:TEIC 0 0 2ā95 ā 2ā95 ā ā ā 
28 
 
RFX:TOL 0 0 0ā44 ā 0ā44 ā ā ā 
RFX:VAN 1 1 1ā08 1ā08 ā ā ā ā 
RID:SUR 0 0 0ā63 ā 0ā63 ā ā ā 
RID:TEIC 0 0 1ā54 ā 1ā54 ā ā ā 
RID:TOL 0 0 0ā23 ā 0ā23 ā ā ā 
RID:VAN 1 0ā78 0ā57 0ā56 0ā58 -0ā98 0ā03 0ā9790 
SUR:TEIC 0 0 2ā44 ā 2ā44 ā ā ā 
SUR:TOL 0 0 0ā36 ā 0ā36 ā ā ā 
SUR:VAN 2 1 0ā9 0ā9 ā ā ā ā 
TEIC:TOL 0 0 0ā15 ā 0ā15 ā ā ā 
TEIC:VAN 2 0ā9 0ā37 0ā38 0ā3 1ā27 0ā15 0ā8826 
TOL:VAN 3 0ā9 2ā48 2ā48 2ā54 -0ā97 0ā06 0ā9500 
 
 Legend: 
 comparison - Treatment comparison 
 k          - Number of studies providing direct evidence 
 prop       - Direct evidence proportion 
 nma        - Estimated treatment effect (OR) in network meta-analysis 
 direct     - Estimated treatment effect (OR) derived from direct evidence 
 indir.     - Estimated treatment effect (OR) derived from indirect evidence 
 RoR        - Ratio of Ratios (direct versus indirect) 
 z          - z-value of test for disagreement (direct versus indirect) 
 p-value    - p-value of test for disagreement (direct versus indirect) 
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Appendix 12. Sustained symptomatic cure NMA after removal of Teasley 1983 RCT 
 
a) Forest plot 
 
 
 
b)     Heterogeneity assessment 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0; I^2 = 0% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
   Q d.f. p-value 
Total  13ā03 15 0ā6001 
Within designs 8ā66 8 0ā3716 
Between designs 4ā37 7 0ā7368 
 
Design-specific decomposition of within-designs Q statistic 
 
Design  Q df p-value 
VAN:BAC  0ā48 1 0ā4898 
VAN:FID  2ā66 4 0ā6168 
VAN:SUR  2ā23 1 0ā1358 
VAN:MET:TOL 3ā30 2 0ā1918 
 
Between-designs Q statistic after detaching of single designs 
 
Detached design Q df p-value 
FID:RID  4ā37 6 0ā6273 
FUA:MET  2ā46 6 0ā8729 
MET:NIT  4ā32 6 0ā6341 
VAN:FID  4ā37 6 0ā6273 
VAN:MET  3ā19 6 0ā7846 
VAN:NIT  4ā32 6 0ā6341 
VAN:RID  4ā37 6 0ā6273 
VAN:TEIC  4ā34 6 0ā6304 
VAN:TOL  3ā38 6 0ā7593 
VAN:FUA:MET:TEIC 1ā96 4 0ā7423 
VAN:MET:TOL 2ā96 5 0ā7056 
 
Q statistic to assess consistency under the assumption of 
a full design-by-treatment interaction random effects model 
 
   Q df p-value tau.within  tau2.within 
Between designs 4ā21 7 0ā7556 0ā0708  0ā005 
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Appendix 13. Comparison-adjusted funnel plot for sustained symptomatic cure 
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Appendix 14. Sensitivity analysis for sustained symptomatic cure: non-blinded studies excluded 
 
De Lalla 1992, Mullane 2015, Teasley 1983, Thabit 2016, Wenisch 1996, Mitra 2017, Guery 2017 RCTs  
excluded 
 
a)    Forest plot. Vancomycin as reference 
 
 
 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0ā0052; I^2 = 7ā5% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
   Q dāf. p-value 
Total  9ā73 9 0ā3726 
Within designs 7ā77 6 0ā2556 
Between designs 1ā96 3 0ā5800 
 
b)    League tableā  
0ā8566           
RID 0ā8266          
0ā83 [0ā35;  
1ā93] FID 0ā7262         
0ā81 [0ā22;  
3ā05] 
0ā99 [0ā34;  
2ā87] CAD 0ā6125        
0ā63 [0ā27;  
1ā51] 
0ā77 [0ā52;  
1ā13] 
0ā78 [0ā26;  
2ā30] SUR 0ā5729       
0ā61 [0ā20;  
1ā89] 
0ā74 [0ā33;  
1ā68] 
0ā75 [0ā20;  
2ā76] 
0ā96 [0ā42;  
2ā23] FUA 0ā5259      
0ā57 [0ā20;  
1ā63] 
0ā69 [0ā34;  
1ā40] 
0ā70 [0ā20;  
2ā41] 
0ā90 [0ā44;  
1ā87] 
0ā94 [0ā36;  
2ā44] NIT 0ā4935     
0ā56 [0ā25;  
1ā27] 
0ā68 [0ā54;  
0ā87] 
0ā69 [0ā24;  
1ā95] 
0ā89 [0ā65;  
1ā20] 
0ā92 [0ā42;  
2ā01] 
0ā98 [0ā51;  
1ā90] VAN 0ā4460    
0ā52 [0ā19;  
1ā40] 
0ā63 [0ā34;  
1ā17] 
0ā64 [0ā19;  
2ā09] 
0ā82 [0ā43;  
1ā57] 
0ā85 [0ā32;  
2ā24] 
0ā91 [0ā38;  
2ā18] 
0ā92 [0ā52;  
1ā64] RFX 0ā2121   
0ā38 [0ā16;  
0ā91] 
0ā46 [0ā32;  
0ā68] 
0ā47 [0ā16;  
1ā39] 
0ā61 [0ā40;  
0ā93] 
0ā63 [0ā30;  
1ā30] 
0ā67 [0ā36;  
1ā26] 
0ā68 [0ā51;  
0ā92] 
0ā74 [0ā39;  
1ā41] MET 0ā2091  
0ā34 [0ā11;  
1ā08] 
0ā41 [0ā17;  
0ā97] 
0ā42 [0ā11;  
1ā57] 
0ā53 [0ā22;  
1ā29] 
0ā55 [0ā18;  
1ā73] 
0ā59 [0ā21;  
1ā70] 
0ā60 [0ā26;  
1ā37] 
0ā65 [0ā24;  
1ā78] 
0ā88 [0ā37;  
2ā12] BAC 0ā0186 
0ā22 [0ā09;  
0ā52] 
0ā27 [0ā19;  
0ā38] 
0ā27 [0ā09;  
0ā79] 
0ā35 [0ā23;  
0ā52] 
0ā36 [0ā17;  
0ā78] 
0ā38 [0ā20;  
0ā75] 
0ā39 [0ā30;  
0ā51] 
0ā42 [0ā23;  
0ā80] 
0ā57 [0ā43;  
0ā76] 
0ā65 [0ā27;  
1ā55] TOL 
League table of pairwise comparisons in network meta-analysis of sensitivity analysis including only 
blinded trials for sustained symptomatic cure. Treatments order in the rank of their chance of being the best 
treatment. Numbers in grey boxes are P-Scores, which are used to rank the treatments. Treatment estimates are provided as odds 
ratios with 95% confidence intervals. Significant pairwise comparisons are highlighted. BAC ± bacitracin, CAD - cadazolid, FID - 
fidaxomicin, FUA ± fusidic acid, MET ± metronidazole, NIT ± nitazoxanide, RFX ± rifaximin, RID ± ridinidazole, SUR ± 
suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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Appendix 15. Sensitivity analysis for sustained symptomatic cure: trials published before 1990 excluded 
Dudley 1986, Teasley 1983 and Young 1985 trials excluded 
 
a) Forest plot 
 
 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0; I^2 = 0% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
   Q d.f. p-value 
Total  12ā55 14 0ā5621 
Within designs  8ā19 7 0ā3166 
Between designs 4ā37 7 0ā7368 
 
b) League table 
0ā9309            
TEIC 0ā8192           
0ā66 [0ā20; 
2ā16] RID 0ā7798          
0ā56 [0ā21; 
1ā47] 
0ā84 [0ā41; 
1ā74] FID 0ā6833         
0ā54 [0ā13; 
2ā20] 
0ā82 [0ā23; 
2ā86] 
0ā97 [0ā34; 
2ā78] CAD 0ā5613        
0ā42 [0ā16; 
1ā12] 
0ā63 [0ā29; 
1ā35] 
0ā75 [0ā53; 
1ā06] 
0ā77 [0ā26; 
2ā24] SUR 0ā4876       
0ā38 [0ā12; 
1ā18] 
0ā58 [0ā22; 
1ā50] 
0ā68 [0ā35; 
1ā34] 
0ā70 [0ā21; 
2ā37] 
0ā91 [0ā45; 
1ā85] NIT 0ā4598      
0ā38 [0ā15; 
0ā97] 
0ā57 [0ā28; 
1ā15] 
0ā67 [0ā55; 
0ā82] 
0ā69 [0ā25; 
1ā94] 
0ā90 [0ā68; 
1ā19] 
0ā98 [0ā51; 
1ā88] VAN 0ā4099     
0ā35 [0ā12; 
1ā04] 
0ā52 [0ā21; 
1ā28] 
0ā62 [0ā34; 
1ā12] 
0ā64 [0ā20; 
2ā06] 
0ā83 [0ā44; 
1ā55] 
0ā91 [0ā39; 
2ā13] 
0ā92 [0ā53; 
1ā61] RFX 0ā3474    
0ā30 [0ā08; 
1ā17] 
0ā45 [0ā13; 
1ā52] 
0ā54 [0ā20; 
1ā46] 
0ā55 [0ā13; 
2ā29] 
0ā72 [0ā26; 
1ā99] 
0ā79 [0ā24; 
2ā54] 
0ā80 [0ā30; 
2ā13] 
0ā87 [0ā28; 
2ā68] LFF571 0ā3251   
0ā30 [0ā11; 
0ā87] 
0ā46 [0ā18; 
1ā17] 
0ā54 [0ā29; 
1ā03] 
0ā56 [0ā17; 
1ā85] 
0ā73 [0ā37; 
1ā42] 
0ā79 [0ā34; 
1ā84] 
0ā81 [0ā44; 
1ā49] 
0ā88 [0ā38; 
2ā00] 
1ā01 [0ā32; 
3ā21] FUA 0ā1860  
0ā26 [0ā10; 
0ā67] 
0ā39 [0ā18; 
0ā83] 
0ā46 [0ā33; 
0ā64] 
0ā47 [0ā16; 
1ā37] 
0ā61 [0ā41; 
0ā91] 
0ā67 [0ā36; 
1ā25] 
0ā68 [0ā52; 
0ā90] 
0ā74 [0ā40; 
1ā38] 
0ā86 [0ā31; 
2ā37] 
0ā85 [0ā48; 
1ā50] MET 0ā0097 
0ā15 [0ā06; 
0ā39] 
0ā22 [0ā10; 
0ā47] 
0ā26 [0ā19; 
0ā36] 
0ā27 [0ā09; 
0ā78] 
0ā35 [0ā24; 
0ā51] 
0ā38 [0ā20; 
0ā74] 
0ā39 [0ā31; 
0ā50] 
0ā42 [0ā23; 
0ā78] 
0ā49 [0ā18; 
1ā35] 
0ā48 [0ā26; 
0ā90] 
0ā57 [0ā44; 
0.75] TOL 
League table of pairwise comparisons in network meta-analysis of sensitivity analysis including only trials published after 
1990. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which are 
used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant pairwise 
comparisons are highlighted. CAD- Cadazolid, FID- Fidaxomicin, FUA ± Fusidic acid, MET ± metronidazole, NIT ± 
nitazoxanide, RFX ± rifaxamicin, RID ± ridinidazole, SUR ± suratomycin, TEIC ± teicoplanin, TOL ± tolevamer, VAN ± 
vancomycin. 
 
Appendix 16. Sensitivity analysis for sustained symptomatic cure: trials published before 2000 excluded 
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Dudley 1986, Teasley 1983 and Young 1985, De Lalla 1992 and Wenisch 1996 trials excluded 
a) Forest plot 
 
 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0; I^2 = 0% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
  Q d.f. p-value 
Total  10ā15 11 0ā5170 
Within designs 8ā19 7 0ā3166 
Between designs 1ā96 4 0ā7423 
 
b) League table 
 
0ā8632           
RID 0ā8271          
0ā84 [0ā41; 
1ā74] FID 0ā7158         
0ā82 [0ā23; 
2ā86] 
0ā97 [0ā34; 
2ā78] CAD 0ā5828        
0ā63 [0ā29; 
1ā35] 
0ā75 [0ā53; 
1ā06] 
0ā77 [0ā26; 
2ā24] SUR 0ā5566       
0ā62 [0ā22; 
1ā75] 
0ā73 [0ā33; 
1ā61] 
0ā75 [0ā21; 
2ā71] 
0ā98 [0ā43; 
2ā21] FUA 0ā5060      
0ā58 [0ā22; 
1ā51] 
0ā68 [0ā35; 
1ā35] 
0ā70 [0ā21; 
2ā38] 
0ā91 [0ā45; 
1ā86] 
0ā94 [0ā36; 
2ā40] NIT 0ā4697     
0ā57 [0ā28; 
1ā15] 
0ā67 [0ā55; 
0ā82] 
0ā69 [0ā25; 
1ā94] 
0ā90 [0ā68; 
1ā19] 
0ā92 [0ā43; 
1ā97] 
0ā98 [0ā51; 
1ā88] VAN 0ā4221    
0ā52 [0ā21; 
1ā28] 
0ā62 [0ā34; 
1ā12] 
0ā64 [0ā20; 
2ā06] 
0ā83 [0ā44; 
1ā55] 
0ā85 [0ā33; 
2ā18] 
0ā91 [0ā38; 
2ā13] 
0ā92 [0ā53; 
1ā61] RFX 0ā3600   
0ā45 [0ā13; 
1ā52] 
0ā54 [0ā20; 
1ā46] 
0ā55 [0ā13; 
2ā29] 
0ā72 [0ā26; 
1ā99] 
0ā73 [0ā21; 
2ā55] 
0ā79 [0ā24; 
2ā55] 
0ā80 [0ā30; 
2ā13] 
0ā87 [0ā28; 
2ā68] LFF571 0ā1867  
0ā39 [0ā18; 
0ā83] 
0ā46 [0ā32; 
0ā65] 
0ā47 [0ā16; 
1ā38] 
0ā61 [0ā41; 
0ā92] 
0ā63 [0ā31; 
1ā28] 
0ā67 [0ā36; 
1ā25] 
0ā68 [0ā51; 
0ā91] 
0ā74 [0ā40; 
1ā39] 
0ā86 [0ā31; 
2ā38] MET 0ā0100 
0ā22 [0ā10; 
0ā47] 
0ā26 [0ā19; 
0ā36] 
0ā27 [0ā09; 
0ā78] 
0ā35 [0ā24; 
0ā51] 
0ā36 [0ā17; 
0ā77] 
0ā38 [0ā20; 
0ā74] 
0ā39 [0ā30; 
0ā50] 
0ā42 [0ā23; 
0ā78] 
0ā49 [0ā18; 
1ā35] 
0ā57 [0ā44; 
0ā75] TOL 
League table of pairwise comparisons in network meta-analysis of sensitivity analysis including only trials published after 
2000. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which are 
used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant pairwise 
comparisons are highlighted. CAD - cadazolid, FID - fidaxomicin, FUA ± fusidic acid, MET ± metronidazole, NIT ± 
nitazoxanide, RFX ± rifampicin, RID ± ridinidazole, SUR ± suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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Appendix 17. Sensitivity analysis for sustained symptomatic cure: trials with less than 50 patients in each arm were 
excluded 
Remaining RCTs: Zar 2007, Wullt 2004, Vickers 2017, Louie 2011, Cornerly 2012, Boix 2017, Lee 2016, Louie 2006, 
Johnson 2014 (301) and Johnson 2014 (302), Pardi 2012, NCT02179658 2016, Guery 2017 
 
a) Forest plot 
 
 
Quantifying heterogeneity / inconsistency: 
tau^2 = 0ā0078; I^2 = 13ā1% 
 
Tests of heterogeneity (within designs) and inconsistency (between designs): 
  Q d.f. p-value 
Total  9ā20 8 0ā3253 
Within designs 7ā29 6 0ā2947 
Between designs 1ā91 2 0ā3843 
 
b)  League table 
 
0ā8742        
RID 0ā8484       
0ā83 [0ā35; 1ā93] FID 0ā6131      
0ā64 [0ā26; 1ā53] 0ā77 [0ā53; 1ā13] SUR 0ā5654     
0ā61 [0ā19; 1ā89] 0ā73 [0ā32; 1ā67] 0ā95 [0ā41; 2ā23] FUA 0ā4760    
0ā56 [0ā25; 1ā28] 0ā68 [0ā55; 0ā85] 0ā88 [0ā65; 1ā21] 0ā93 [0ā42; 2ā05] VAN 0ā4333   
0ā52 [0ā19; 1ā42] 0ā63 [0ā34; 1ā17] 0ā81 [0ā42; 1ā58] 0ā86 [0ā32; 2ā29] 0ā92 [0ā51; 1ā65] RFX 0ā1882  
0ā38 [0ā16; 0ā91] 0ā46 [0ā32; 0ā67] 0ā60 [0ā39; 0ā93] 0ā63 [0ā30; 1ā31] 0ā68 [0ā50; 0ā92] 0ā73 [0ā38; 1ā42] MET 0ā0015 
0ā22 [0ā09; 0ā52] 0ā27 [0ā19; 0ā38] 0ā34 [0ā23; 0ā52] 0ā36 [0ā16; 0ā80] 0ā39 [0ā30; 0ā51] 0ā42 [0ā22; 0ā80] 0ā58 [0ā43; 0ā77] TOL 
 
League table of pairwise comparisons in network meta-analysis of sensitivity analysis including only trials having 50 or 
more patients in each arm. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are 
P-Scores, which are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. 
Significant pairwise comparisons are highlighted. FID - fidaxomicin, FUA ± fusidic acid, MET ± metronidazole, RFX ± 
rifaximicin, RID ± ridinidazole, SUR ± suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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Appendix 18. Subgroup analyses 
 
a)   Severe CDI 
Data available from Zar 2007, Vickers 2017, Mucher 2009, Louie 2011, Cornely 2012, Lee 2016, Johnson 2014  
(301) and Johnson 2014 (302) trials 
 
i) Forest plot 
 
 
ii) League table 
 
0.8070       
RID 0ā7830      
0ā66 [0ā07;  5ā92] FID 0ā6692     
0ā58 [0ā03; 10ā00] 0ā89 [0ā12;  6ā75] NIT 0ā5385    
0ā37 [0ā05;  3ā06] 0ā57 [0ā30;  1ā11] 0ā64 [0ā09;  4ā37] VAN 0ā3570   
0ā25 [0ā03;  2ā28] 0ā39 [0ā16;  0ā97] 0ā44 [0ā06;  3ā29] 0ā68 [0ā36;  1ā28] MET 0ā2149  
0ā09 [0ā00;  4ā93] 0ā13 [0ā00;  4ā44] 0ā15 [0ā00;  7ā71] 0ā23 [0ā01;  7ā30] 0ā34 [0ā01; 11ā39] SUR 0ā1305 
0ā14 [0ā02;  1ā29] 0ā21 [0ā08;  0ā57] 0ā24 [0ā03;  1ā86] 0ā37 [0ā18;  0ā77] 0ā55 [0ā28;  1ā10] 1ā62 [0ā05; 55ā26] TOL 
 
League table of subgroup pairwise comparisons in network meta-analysis of severe Clostridium difficile infection 
treatment. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which 
are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID - fidaxomicin, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, sUR ± 
Suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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b)  Non-severe CDI 
Data available from Zar 2007, Vickers 2017, Mucher 2009, Louie 2011, Cornely 2012, Lee 2016, Johnson 2014  
(301) and Johnson 2014 (302) trials 
 
i) Forest plot 
 
 
ii) League table 
 
0ā8771       
RID 0ā7926      
0ā77 [0ā28; 2ā10] FID 0ā6762     
0ā62 [0ā20; 1ā94] 0ā80 [0ā39; 1ā67] SUR 0ā5263    
0ā45 [0ā07; 3ā09] 0ā59 [0ā11; 3ā24] 0ā73 [0ā12; 4ā40] NIT 0ā4092   
0ā36 [0ā14; 0ā93] 0ā47 [0ā33; 0ā66] 0ā59 [0ā31; 1ā12] 0ā80 [0ā15; 4ā26] VAN 0ā2066  
0ā23 [0ā08; 0ā64] 0ā30 [0ā18; 0ā50] 0ā37 [0ā18; 0ā79] 0ā51 [0ā09; 2ā84] 0ā64 [0ā43; 0ā94] MET 0ā0121 
0ā13 [0ā05; 0ā35] 0ā16 [0ā10; 0ā27] 0ā21 [0ā10; 0ā43] 0ā28 [0ā05; 1ā55] 0ā35 [0ā25; 0ā50] 0ā55 [0ā39; 0ā78] TOL 
 
League table of subgroup pairwise comparisons in network meta-analysis of non-severe Clostridium difficile infection 
treatment. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which 
are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID - fidaxomicin, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, sUR ± 
Suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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c) Treatment of initial CDI 
Data available from Wullt 2004, Vickers 2017, Mucher 2009, Louie 2011, Cornely 2012, Lee 2016, Johnson 2014  
(301) and Johnson 2014 (302) trials 
 
i) Forest plot 
 
 
ii) League table 
 
0ā8389        
RID 0ā7816       
0ā83 [0ā32; 2ā13] FID 0ā7233      
0ā77 [0ā25; 2ā36] 0ā92 [0ā44; 1ā95] SUR 0ā5757     
0ā60 [0ā12; 3ā05] 0ā73 [0ā18; 2ā90] 0ā79 [0ā17; 3ā58] NIT 0ā4989    
0ā51 [0ā15; 1ā72] 0ā62 [0ā26; 1ā47] 0ā67 [0ā23; 1ā94] 0ā85 [0ā18; 4ā13] FUA 0ā3791   
0ā43 [0ā18; 1ā05] 0ā52 [0ā38; 0ā70] 0ā56 [0ā28; 1ā11] 0ā71 [0ā18; 2ā76] 0ā84 [0ā37; 1ā90] VAN 0ā1997  
0ā32 [0ā12; 0ā86] 0ā39 [0ā24; 0ā64] 0ā42 [0ā19; 0ā93] 0ā53 [0ā13; 2ā19] 0ā63 [0ā31; 1ā28] 0ā75 [0ā50; 1ā12] MET 0ā0029 
0ā14 [0ā05; 0ā36] 0ā17 [0ā11; 0ā27] 0ā18 [0ā08; 0ā39] 0ā23 [0ā06; 0ā93] 0ā27 [0ā12; 0ā60] 0ā32 [0ā23; 0ā46] 0ā43 [0ā31; 0ā61] TOL 
League table of subgroup pairwise comparisons in network meta-analysis of initial Clostridium difficile infection 
treatment. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which 
are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID- Fidaxomicin, FUA ± Fusidic acid, MET ± Metronidazole, NIT ± Nitazoxanide, RID ± 
Ridinidazole, SUR ± Suratomycin, TOL ± Tolevamer, VAN ± Vancomycin. 
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d)   Non-initial CDI 
Data available from Vickers 2017, Mucher 2009, Louie 2011, Cornely 2012, Lee 2016, Johnson 2014 (301) and  
Johnson 2014 (302) trials 
 
i) Forest plot 
 
 
ii) League table 
 
0ā8226       
FID 0ā7688      
1ā20 [0ā11; 12ā54] RID 0ā5897     
0ā59 [0ā12;  2ā83] 0ā49 [0ā03;  7ā18] SUR 0ā5082    
0ā45 [0ā24;  0ā84] 0ā37 [0ā04;  3ā61] 0ā76 [0ā18;  3ā23] VAN 0ā3879   
0ā30 [0ā01;  8ā60] 0ā25 [0ā00; 13ā66] 0ā51 [0ā01; 18ā64] 0ā67 [0ā02; 18ā06] NIT 0ā2186  
0ā26 [0ā10;  0ā64] 0ā22 [0ā02;  2ā27] 0ā44 [0ā09;  2ā14] 0ā57 [0ā30;  1ā11] 0ā86 [0ā03; 24ā87] TOL 0ā2042 
0ā25 [0ā09;  0ā66] 0ā21 [0ā02;  2ā25] 0ā42 [0ā08;  2ā14] 0ā56 [0ā27;  1ā16] 0ā83 [0ā03; 24ā48] 0ā97 [0ā54;  1ā75] MET 
 
League table of subgroup pairwise comparisons in network meta-analysis of non-initial Clostridium difficile infection 
treatment. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, which 
are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID - fidaxomicin, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, SUR ± 
suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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e) > 65 years old 
Data available from Vickers 2017, Louie 2011, Cornely 2012, Lee 2016, Johnson 2014 (301) and Johnson 2014  
(302) trials 
 
i) Forest plot (Vancomycin as reference)  
 
 
ii) League table 
 
0ā9205      
FID 0ā6759     
0ā68 [0ā18; 2ā54] RID 0ā5676    
0ā54 [0ā38; 0ā77] 0ā79 [0ā22; 2ā77] VAN 0ā5530   
0ā53 [0ā19; 1ā47] 0ā78 [0ā16; 3ā76] 0ā99 [0ā38; 2ā55] SUR 0ā2727  
0ā33 [0ā18; 0ā61] 0ā49 [0ā13; 1ā87] 0ā62 [0ā39; 1ā00] 0ā63 [0ā22; 1ā80] MET 0ā0104 
0ā19 [0ā11; 0ā32] 0ā27 [0ā07; 1ā02] 0ā35 [0ā23; 0ā52] 0ā35 [0ā12; 0ā98] 0ā56 [0ā37; 0ā83] TOL 
League table of subgroup pairwise comparisons in network meta-analysis of Clostridium difficile infection treatment for 
patients aged >65. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, 
which are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID - fidaxomicin, MET ± metronidazole, NIT ± nitazoxanide, RID ± ridinidazole, SUR ± 
suratomycin, TOL ± tolevamer, VAN ± vancomycin. 
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f) < 65 years old 
Data available from Vickers 2017, Louie 2011, Cornely 2012, Lee 2016, Johnson 201 (301) and Johnson (302) trials 
 
i) Forest plot (Vancomycin as reference) 
 
ii)         League table  
0ā9216      
RID 0ā7418     
0ā57 [0ā14; 2ā32] SUR 0ā7244    
0ā54 [0ā16; 1ā83] 0ā96 [0ā38; 2ā39] FID 0ā376   
0ā26 [0ā08; 0ā80] 0ā45 [0ā20; 1ā02] 0ā47 [0ā31; 0ā71] VAN 0ā2359  
0ā20 [0ā06; 0ā69] 0ā35 [0ā13; 0ā91] 0ā36 [0ā19; 0ā70] 0ā77 [0ā46; 1ā29] MET 0ā0003 
0ā10 [0ā03; 0ā35] 0ā18 [0ā07; 0ā46] 0ā19 [0ā10; 0ā35] 0ā40 [0ā25; 0ā63] 0ā52 [0ā34; 0.80] TOL 
League table of subgroup pairwise comparisons in network meta-analysis of Clostridium difficile infection treatment for 
patients aged <65. Treatments order in the rank of their chance of being the best treatment. Numbers in grey boxes are P-Scores, 
which are used to rank the treatments. Treatment estimates are provided as odds ratios with 95% confidence intervals. Significant 
pairwise comparisons are highlighted. FID - fidaxomicin, MET ± metronidazole, RID ± ridinidazole, SUR ± suratomycin, TOL ± 
tolevamer, VAN ± vancomycin. 
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Appendix 19.   Confidence in sustained symptomatic cure estimates by GRADE system (per Salanti et al. 2014) 
 
Comparison Study limitations Imprecision 
OR [95% CI] 
Heterogeneity and inconsistency Indirectness Publication bias Confidence in odds ratio 
for sustained 
symptomatic cure 
VAN vs RFX 100% of estimate from 
studies of moderate risk.  
0ā92 [0ā53; 1ā61] Evidence from only one direct 
comparison study. No heterogeneity and 
inconsistency. 
Only one trial. No subgroup 
analyses to assess transitivity. 
Only one study. 
Unpublished, but provided 
by authors. RFX treatment 
effect inferior to VAN. 
Bias undetectable by 
conventional methods.  
Very low  
(downgrade by 3 levels for 
study limitations, 
imprecision and 
indirectness) 
VAN vs SUR 100% estimate from 
studies of low risk 
0.90 [0ā68; 1ā19] Moderate heterogeneity as assessed by 
Cochran¶V Q 2ā22 and p-value = 0ā13. 
Boix et al. 2017 trial included 
significantly higher proportion of 
patients with severe CDI compared to 
Lee et al. 2016 trial.  
Only direct evidence, no node-splitting 
inconsistency.  
Subgroup analyses provide slightly 
different efficacy of SUR and 
VAN for different subgroups.   
No publication bias 
detectable by conventional 
methods.  
Low  
(downgrade by 2 levels for 
heterogeneity and 
imprecision) 
VAN vs TEIC 100% of estimate from 
studies with high risk of 
bias. 
0ā37 [0ā14; 0ā94] Very low heterogeneity as assessed by 
Cochran¶V Q 0ā015 and p-value = 0ā90.  
Both direct and indirect effect estimates 
very similar.  
Not enough patient information to 
assess transitivity.  
 
Only two old unregistered 
trials. No publication bias 
detected by conventional 
methods. One very small 
old trial excluded for not 
reporting recurrence and 
therefore making sustained 
symptomatic cure 
assessment impossible 
(Boero et al. 1990). There 
exists likelihood of other 
old unpublished trials.  
Very low  
(downgrade by 2 levels for 
study limitations, by 1 level 
for indirectness and by 1 
level for publication bias. 
Upgrade by 1 level for 
large effect size) 
VAN vs RID 22% of estimate from 
studies with high risk of 
bias, 78% from studies 
with low risk of bias 
0ā57 [0ā28; 1ā15] Evidence from two trials with different 
comparators. No heterogeneity.  
Nearly identical estimates from direct 
and indirect evidence.  
Identical treatment in both trials. 
Similar effect sizes across different 
patient groups. 
No publication bias 
detectable by conventional 
methods. One trial 
provided by 
pharmaceutical company. 
Other unpublished RCTs 
unlikely. 
Moderate  
(downgrade by 1 level for 
imprecision) 
VAN vs TOL 100% of estimate from 
studies with moderate 
risk of bias 
0ā40 [0ā32; 0ā51] Moderate heterogeneity as assessed by 
CochranµV Q (2ā22) and P-value (0ā33).  
Both direct and indirect effect estimates 
very similar.  
 
Two different TOL doses in Louie 
2006 compared to Johnson et al. 
2014 trials. Consistent and similar 
effect sizes across different patient 
groups. 
No publication bias 
detectable by conventional 
methods. 
Moderate  
(downgrade by 2 levels for 
study limitations and 
heterogeneity. Upgrade by 
1 level for large effect 
size). 
NIT vs VAN 71% of estimate from 
studies with high risk of 
bias, 29% of estimate 
from studies with low 
risk of bias 
0ā93 [0ā49; 1ā78] No heterogeneity for one direct study. 
Both direct and indirect effect estimates 
very similar.  
 
Similar treatments and patient 
groups. Similar treatment effect 
size in subgroup analyses. 
No publication bias 
detectable by conventional 
methods. 
Low  
(downgrade by 2 levels for 
study limitations and 
imprecision) 
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VAN vs LFF571 100% of estimate from 
trials with high risk of 
bias 
0ā80 [0ā30; 2ā13] Evidence from only one direct 
comparison study. No heterogeneity and 
inconsistency. 
Only one trial. No subgroup 
analyses to assess transitivity. 
No publication bias 
detectable by conventional 
methods. 
Very low  
(downgrade by 2 levels for 
study limitations, by 1 level 
for imprecision and by 1 
level for indirectness) 
VAN vs MET 19% of estimate from 
trials with high risk of 
bias, 81% from trials 
with moderate risk of 
bias. 
0ā73 [0ā56; 0ā95] Moderate heterogeneity as assessed by 
CochranµV Q (4ā12) and P-value (0ā38). 
This is largely due to Teasley et al. 1983 
study, which demonstrated a higher 
treatment effect for metronidazole than 
later better quality RCTs. Removal of 
Teasley trial resolved heterogeneity, but 
did not significantly affect the effect 
estimate.  
Direct and indirect effect estimates 
similar.  
Similar treatment regime and 
patient groups across trials. 
Consistent treatment effect size 
across different subgroups.  
No publication bias 
detectable by conventional 
methods, older unpublished 
trials possible, but unlikely 
to affect treatment effect 
estimate significantly, 
unless unpublished RCT is 
very large.  
Moderate  
(downgrade by 1 level for 
study limitations) 
CAD vs VAN 100% of estimate from 
trials with low risk of 
bias 
0ā69 [0ā25; 1ā94] Evidence from only one direct 
comparison study. No heterogeneity and 
inconsistency. 
Only one trial. No subgroup 
analyses to assess transitivity. 
Two very large phase 3 
trials have been finished 
but were not published at 
the time of the analysis. 
They are likely to change 
the treatment effect 
estimate. 
Very low  
(downgrade by 3 levels for 
imprecision, indirectness 
and publication bias) 
FID vs VAN 20% of estimate from 
trials with high risk, 13% 
with moderate risk, 67% 
from low risk of bias 
0ā67 [0ā55; 0ā82] Mild heterogeneity as assessed by 
CochranµV Q (2ā62) and P-value (0ā62). 
Direct and indirect effect estimates very 
similar. 
One trial assessed slightly 
prolonged FID dosing regime. 
Unlikely to affect the overall effect 
estimate. 
Consistent treatment effect size 
across different subgroups. 
No publication bias 
detectable by conventional 
methods.  
Two registered, but 
unpublished trials 
uncovered. Further 
unpublished data unlikely.  
High 
VAN vs FUA 28% of estimate from 
trials with high risk, 72% 
from moderate risk of 
bias.  
0ā85 [0ā47; 1ā57] Direct evidence from one trial. No 
heterogeneity. 
Significantly different estimates from 
direct and indirect evidence (RoR 1ā83).  
Different doses in two trials. Not 
enough information to assess 
transitivity.  
No publication bias 
detectable by conventional 
methods.  
 
Very low  
(downgrade by 4 levels for 
study limitations, 
imprecision, inconsistency 
and indirectness)  
VAN vs BAC 60% of estimate from 
trials with high risk of 
bias, 40% from moderate 
risk of bias.  
0ā60 [0ā26; 1ā36] Mild heterogeneity as assessed by 
CochranµV Q (0ā48) and P-value (0ā49).  
Evidence from two direct trials, no 
indirect estimate possible. 
No subgroup analyses to assess 
transitivity. 
No publication bias 
detectable by conventional 
methods. Old unregistered 
unpublished trials possible.  
Very low  
(downgrade by 2 levels for 
study limitations, by 1 level 
for indirectness) 
RID vs FID 23% of estimate from 
trials of high risk of bias. 
77% from low risk of 
bias. Direct evidence is 
of high risk of bias.  
0ā84 [0ā41; 1ā74] Direct evidence from only one trial. No 
heterogeneity. 
Direct and indirect effect estimates very 
similar. 
Similar treatment effect size across 
subgroups. Treatments in both 
trials identical.   
No publication bias 
detectable by conventional 
methods. Further 
unpublished data unlikely. 
Moderate  
(downgrade by 1 level for 
imprecision) 
FUA vs MET 31% of estimate from 
trials with high risk of 
bias, 69% from trials 
with moderate risk of 
bias.  
0ā86 [0ā48; 1ā52] Moderate heterogeneity as assessed by 
CochranµV Q (1ā60) and P-value (0ā21).  
Similar direct and indirect estimates of 
treatment effect. 
Different FUA and MET doses 
used in both trials, patient age 
different. Not enough data for 
FUA subgroup analyses.  
No publication bias 
detectable by conventional 
methods. 
Very low  
(downgrade by 3 levels for 
study limitations, 
imprecision and 
indirectness) 
TEIC vs FUA 100% of estimate from 
trials with high risk of 
bias.  
0ā31 [0ā11; 0ā89] Direct evidence from one trial. No 
heterogeneity. 
Significantly different estimates from 
direct and indirect evidence (RoR 2ā01). 
One direct trial. The rest of the 
estimate derived from indirect 
evidence. Insufficient data for 
assessment of transitivity. 
No publication bias 
detectable by conventional 
methods. Old unregistered 
unpublished trials possible. 
Very low  
(downgrade by 2 levels for 
study limitations, by 1 level 
for inconsistency and 1 
level for indirectness. 
43 
 
Upgrade by 1 level for 
large treatment effect) 
NIT vs MET 75% of estimate from 
trials with high risk of 
bias. 25% from trials 
with low risk of bias.  
0ā68 [0ā37; 1ā27] Direct evidence from one trial. No 
heterogeneity.  
Direct and indirect effect estimates 
similar. 
Consistent treatment effects across 
different subgroups.  
No publication bias 
detectable by conventional 
methods. 
Low  
(downgrade by 2 levels for 
study limitations and 
imprecision) 
MET vs TEIC 100% of estimate from 
trials with high risk of 
bias. 
0ā27 [0ā10; 0ā70] Direct evidence from one trial. No 
heterogeneity.  
Significantly different estimates from 
direct and indirect evidence (RoR 0ā47). 
Insufficient data for assessment of 
transitivity. 
No publication bias 
detectable by conventional 
methods. Old unregistered 
unpublished trials possible. 
Very low  
(downgrade by 2 levels for 
study limitations, by 1 level 
for inconsistency and 1 
level for indirectness. 
Upgrade by 1 level for 
large treatment effect) 
MET vs TOL 100% of estimate from 
studies with moderate 
risk of bias. 
0ā55 [0ā42; 0ā72] Moderate heterogeneity as assessed by 
CochranµV Q (1ā75) and P-value (0ā18).  
Direct and indirect effect estimates 
similar. 
Consistent treatment effects across 
different subgroups. 
No publication bias 
detectable by conventional 
methods. 
Moderate 
(downgrade by 2 levels for 
study limitations and 
heterogeneity. Upgrade by 
1 level for large treatment 
effect) 
Ranking of 
treatments  
18% overall estimates 
from trials with high risk 
of bias, 41% from 
moderate risk of bias, 
41% from low risk of 
bias.  
P-score based 
ranking does not 
allow 
quantification of 
ranking 
imprecision.  
There was no global heterogeneity and 
inconsistency (Cochrane Q = 15ā70, p = 
0ā47; I^2 0%; tau^2 = 0) 
The overall patient cohort was 
relatively comparable between 
different interventions. Few trials 
provided enough data for sufficient 
transitivity analysis   
No dominant publication 
bias detectable by 
comparison-adjusted funnel 
plots. 
Low  
(downgrade by 2 levels for 
study limitations and 
indirectness) 
 
Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014; 9(7): e99682. 
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Appendix 20. Results of individual studies 
Study t1 t2 t3 t4 n1 cure1 recu1 ssc1 n2 cure2 recu2 ssc2 n3 cure3 recu3 ssc3 n4 cure4 recu4 ssc4 
Zar 2007 VAN MET 
  
82 69 5 64 90 66 9 57 
        
Wenish 1996 VAN MET TEIC FUA 31 29 5 24 31 29 5 24 28 27 2 25 29 27 8 19 
Wullt 2004 MET FUA 
  
64 51 15 36 67 59 14 45 
        
Young 1985 VAN BAC 
  
21 18 6 12 21 16 5 11 
        
Vickers 2017 RID VAN 
  
50 36 4 32 50 37 12 25 
        
Louie 2011 FID VAN 
  
302 253 39 214 327 265 67 198 
        
Cornerly 2012 FID VAN 
  
270 221 28 193 265 223 60 163 
        
Mullane 2015 LFF571 VAN 
  
46 29 12 17 26 18 7 11 
        
Louie 2015 CAD VAN 
  
62 42 17 25 22 15 8 7 
        
Musher 2006 NIT MET 
  
98 68 17 51 44 28 9 19 
        
Musher 2009 NIT VAN 
  
23 17 1 16 27 20 2 18 
        
Dudley 1986 BAC VAN 
  
31 12 5 7 31 15 3 12 
        
Boix 2017 SUR VAN 
  
308 229 53 176 298 234 63 171 
        
Teasley 1983 MET VAN 
  
45 37 2 35 56 45 6 39 
        
Lee 2016 SUR VAN 
  
139 119 27 92 70 59 21 38 
        
Louie 2006 TOL VAN 
  
190 106 27 79 96 73 16 57 
        
Johnson 2014 (301) TOL VAN MET 
 
285 124 11 113 140 109 27 82 149 103 29 74 
    
Johnson 2014 (302) TOL VAN MET 
 
278 112 13 99 126 101 19 82 140 99 20 79 
    
De Lalla 1992 TEIC VAN 
  
27 25 2 23 24 20 4 16 
        
Thabit 2016 FID VAN 
  
7 6 2 4 5 3 2 1 
        
NCT02179658 2016 FID VAN 
  
106 87 17 70 109 95 24 71 
        
Guery 2017 FID VAN 
  
183 131 7 124 181 136 30 106 
        
Pardi 2012 RFX VAN 
  
119 94 11 83 119 93 8 85 
        
Mitra 2017 RID FID 
  
14 12 5 7 13 8 2 6 
        
t - treatment; n - number of participants randomized intro treatment group; cure - number of participants attaining a primary cure; recu - number of participants experiencing recurrence after 
attaining a primary cure, ssc - number of participants attaining a sustained symptomatic cure 
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Appendix 21. List of ongoing RCTs 
Clinicaltrials.gov 
number Study title Expected finish date 
NCT01959048 Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis December 2017 
NCT02301000 IMT for Primary Clostridium Difficile Infection February 2018 
NCT02857582 Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile December 2017 
NCT02801656 Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea null 
NCT02686645 Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection December 2021 
NCT02326636 Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection May 2018 
NCT02981316 Treatment of Recurrent Clostridium Difficile Infection With RBX7455 November 2018 
NCT03065374 Treatment for Clostridium-difficile Infection With IMM529 May 2018 
NCT02299570 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection January 2018 
NCT03183128 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection June 2019 
NCT03183141 ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection August 2019 
NCT02464306 Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection June 2019 
NCT03053505 A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection October 2018 
NCT02255305 FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI December 2018 
NCT02774382 Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment 
of Recurrent Clostridium Difficile Infections null 
NCT02692651 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections April 2020 
NCT03030248 Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population May 31, 2019 
NCT03110133 Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff May 2019 
NCT02466698 Intestinal Lavage for the Treatment of Severe C. Difficile Infections August 2017 
NCT02667418 Optimal Treatment for Recurrent Clostridium Difficile December 29, 2017 
NCT02570477 FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment December 2017 
 
 
 PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review 
Involving a Network Meta-analysis 
 
Section/Topic Item 
# 
Checklist Item Reported 
on Page # 
TITLE    
Title 1 Identify the report as a systematic review incorporating a 
network meta-analysis (or related form of meta-analysis).  
1 
 
   
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable:  
Background: main objectives 
Methods: data sources; study eligibility criteria, 
participants, and interventions; study appraisal; and synthesis 
methods, such as network meta-analysis.  
Results: number of studies and participants identified; 
summary estimates with corresponding confidence/credible 
intervals; treatment rankings may also be discussed. Authors 
may choose to summarize pairwise comparisons against a 
chosen treatment included in their analyses for brevity. 
Discussion/Conclusions: limitations; conclusions and 
implications of findings. 
Other: primary source of funding; systematic review 
registration number with registry name. 
2-3 
 
   
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is 
already known, including mention of why a network meta-
analysis has been conducted.  
4-5 
Objectives  4 Provide an explicit statement of questions being addressed, 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5 
    
METHODS    
Protocol and 
registration  
5 Indicate whether a review protocol exists and if and where it 
can be accessed (e.g., Web address); and, if available, provide 
registration information, including registration number.  
Appendix 
page 2.  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving 
rationale. Clearly describe eligible treatments included in the 
treatment network, and note whether any have been clustered 
or merged into the same node (with justification).  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
Appendix 
pages 5-8 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
5-6 
PRISMA NMA checklist
Click here to download Necessary additional data: PRISMA NMA checklist.docx
included in the meta-analysis).  
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
7 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
Appendix 
page 3 
Geometry of the 
network 
S1 Describe methods used to explore the geometry of the 
treatment network under study and potential biases related to 
it. This should include how the evidence base has been 
graphically summarized for presentation, and what 
characteristics were compiled and used to describe the 
evidence base to readers. 
7-8 
Risk of bias within 
individual studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used 
in any data synthesis.  
7 
Summary measures  13 State the principal summary measures (e.g., risk ratio, 
difference in means). Also describe the use of additional 
summary measures assessed, such as treatment rankings and 
surface under the cumulative ranking curve (SUCRA) values, 
as well as modified approaches used to present summary 
findings from meta-analyses. 
7-8 
Planned methods of 
analysis 
14 Describe the methods of handling data and combining results 
of studies for each network meta-analysis. This should include, 
but not be limited to:   
x Handling of multi-arm trials; 
x Selection of variance structure; 
x Selection of prior distributions in Bayesian analyses; 
and 
x  Assessment of model fit.  
7 
Assessment of 
Inconsistency 
S2 Describe the statistical methods used to evaluate the agreement 
of direct and indirect evidence in the treatment network(s) 
studied. Describe efforts taken to address its presence when 
found. 
9 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
9 
Additional analyses  16 Describe methods of additional analyses if done, indicating 
which were pre-specified. This may include, but not be limited 
to, the following:  
x Sensitivity or subgroup analyses; 
x Meta-regression analyses;  
x Alternative formulations of the treatment network; and 
x Use of alternative prior distributions for Bayesian 
analyses (if applicable).  
8 
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Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
9-10, 21, 
Appendix 
9-11 
Presentation of 
network structure 
S3 Provide a network graph of the included studies to enable 
visualization of the geometry of the treatment network.  
24 
Summary of 
network geometry 
S4 Provide a brief overview of characteristics of the treatment 
network. This may include commentary on the abundance of 
trials and randomized patients for the different interventions 
and pairwise comparisons in the network, gaps of evidence in 
the treatment network, and potential biases reflected by the 
network structure. 
9-10 
Study 
characteristics  
18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
22-23 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any 
outcome level assessment.  
25, 
appendix 
12-19 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: 1) simple summary data for each intervention 
group, and 2) effect estimates and confidence intervals. 
Modified approaches may be needed to deal with information 
from larger networks. 
 Appendix 
44 
Synthesis of results  21 Present results of each meta-analysis done, including 
confidence/credible intervals. In larger networks, authors may 
focus on comparisons versus a particular comparator (e.g. 
placebo or standard care), with full findings presented in an 
appendix. League tables and forest plots may be considered to 
summarize pairwise comparisons. If additional summary 
measures were explored (such as treatment rankings), these 
should also be presented. 
10-11, 26, 
appendix 
22-25 
Exploration for 
inconsistency 
S5 Describe results from investigations of inconsistency. This 
may include such information as measures of model fit to 
compare consistency and inconsistency models, P values from 
statistical tests, or summary of inconsistency estimates from 
different parts of the treatment network. 
11-12, 
appendix 
22-25, 27-
29 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies 
for the evidence base being studied.  
Appendix 
22-25, 30 
Results of 
additional analyses 
23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression analyses, alternative 
network geometries studied, alternative choice of prior 
distributions for Bayesian analyses, and so forth).  
12-13, 27, 
appendix 
31-42 
    
DISCUSSION    
Summary of 
evidence  
24 Summarize the main findings, including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy-
makers).  
13-15, 
Appendix 
41 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review level (e.g., incomplete retrieval of 
identified research, reporting bias). Comment on the validity of 
13-15 
the assumptions, such as transitivity and consistency. 
Comment on any concerns regarding network geometry (e.g., 
avoidance of certain comparisons). 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
16 
    
FUNDING    
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review. This should also include information 
regarding whether funding has been received from 
manufacturers of treatments in the network and/or whether 
some of the authors are content experts with professional 
conflicts of interest that could affect use of treatments in the 
network. 
3 
 
PICOS = population, intervention, comparators, outcomes, study design. 
* Text in italics indicateS wording specific to reporting of network meta-analyses that has been added to 
guidance from the PRISMA statement. 
Authors may wish to plan for use of appendices to present all relevant information in full detail for 
items in this section. 
